News

 

It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

Corporate news

2018
Evotec and LEO Pharma form drug discovery alliance targeting dermatological conditions
Hamburg, Germany, and Ballerup, Denmark, 04 December 2018

Evotec AG today announced a new integrated drug discovery alliance with LEO Pharma, a global leader in medical dermatology. The collaboration goal is to generate new leads against innovative targets for a range of dermatological conditions and initially runs for two years. The collaboration leverages Evotec’s industry-leading hit identification platform including the extensive screening, structural biology and fragment-based drug design capabilities and expertise together with LEO Pharma’s 110-year track record of drug development and advancing science in dermatology.

Evotec wins Scrip Award 2018 for "Business Development Team of the Year"
Hamburg, Germany, 29 November 2018

Evotec AG announced today that the company won the Scrip Award 2018 for “Business Development Team of the Year”. This particular award recognises the achievements of Evotec’s Business Development Team over the last year, which has been characterised by many new alliances and partnerships between Evotec and partners from the pharmaceutical and biotech industry as well as academic institutes.

LAB282: two years of drug discovery impact
Hamburg, Germany, and Oxford, UK, 22 November 2018

LAB282, a unique funding-expertise hybrid model to accelerate Oxford therapeutics out of the lab and into the wider world, launched two years ago this month.

Read about what it’s achieved so far, and what’s next for the partnership.

Evotec and Immuneering to collaborate on artificial intelligence ("AI") driven ligand identification for rare hereditary metabolic diseases
Hamburg, Germany, and Cambridge, USA, 21 November 2018

Evotec AG today announced that it has entered into a research collaboration with Immuneering Corporation (“Immuneering”), a worldwide leader in data-driven drug discovery, to discover novel small molecules for rare hereditary metabolic diseases. The research collaboration brings together Evotec’s leading induced pluripotent stem cell (“iPSC”) platform and broad drug discovery capabilities with Immuneering’s unique Artificial Intelligence-driven drug discovery platform to accelerate ligand identification for novel targets.

Evotec AG reports first nine-month 2018 results and corporate updates
Hamburg, Germany, 13 November 2018

Evotec AG today reported financial results and corporate updates for the first nine months of 2018: Strong operational and scientific performance; 57% increase in group revenues, 77% increase in adjusted group EBITDA; Strong outlook for 2018 confirmed and good underlying business indications for 2019; Webcast and conference call today at 02.00 pm CET

Evotec wins award for "Sustained Excellence" at Deloitte's Technology Fast 50
Hamburg, Germany, 09 November 2018

Evotec AG announced today that the company has won one of the prestigious “Technology Fast 50” awards with which Deloitte honours the fastest-growing innovation drivers within the technology sector. At yesterday’s award ceremony, Evotec received the prize for “Sustained Excellence” which recognises the Company’s long-term growth, innovation capability, entrepreneurial spirit, as well as its sustainable corporate management.

Evotec to attend upcoming investor conferences
Hamburg, Germany, 07 November 2018

Evotec AG announced today that its management will be presenting and attending the following upcoming conferences:

Jefferies London Healthcare Conference 2018, London, UK

15th Kempen London Conference, London, UK

German Equity Forum 2018, Frankfurt am Main, Germany

16th Berenberg European Conference, Surrey, UK

Evotec AG to report first nine-month 2018 results on 13 November 2018
Hamburg, Germany, 06 November 2018

Evotec AG will report its financial results for the first nine months of 2018 on Tuesday, 13 November 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Evotec Partner Facio Therapies achieves first-ever in vivo proof of principle in FSHD
Hamburg, Germany, 31 October 2018

Evotec partner Facio Therapies (“Facio”) announced today that oral treatment with one of Facio’s lead candidates results in significant reduction of the human muscle-toxic DUX4 protein in mice engrafted with human FSHD-affected muscle cells. Facio is the first in the FSHD field to achieve proof of principle in an animal model (“in vivo”).

NCL foundation together with Evotec and Hamburg University explores new paths in juvenile NCL
Hamburg, Germany, 22 October 2018

NCL foundation announces today that together with the biotechnology Company Evotec AG it supports a three-year PhD programme for research into juvenile neuronal ceroid lipofuscinosis (NCL). Under scientific supervision by Dr Guido Hermey (Hamburg University), the PhD programme will be based in the facilities and laboratories of Evotec AG. 

Evotec and Ferring form strategic research alliance in reproductive medicine and women`s health
Hamburg, Germany, 17 October 2018

Evotec AG and Ferring Pharmaceuticals today announced a strategic research alliance to discover and develop new small molecule therapies to treat patients living with fertility and gynaecological conditions.

Evotec and Celgene expand iPSC collaboration to include additional cell lines
Hamburg, Germany, 11 October 2018

Evotec AG announced today that the Company will receive a $ 6 m payment from Celgene following Celgene’s decision to expand the collaboration to include additional cell lines. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’ symptoms and there is a huge unmet medical need for therapeutic modalities that slow down or reverse disease progression.

Evotec signs agreement with Sanofi to advance early stage academic research into novel therapeutic candidates
Hamburg, Germany, 04 October 2018

Evotec AG announced today that it has established an initiative with Sanofi through the launch of a newly created BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas.

LAB150 awards its second drug discovery project from Canada’s largest research based Hospital, The University Health Network (UHN)
Toronto, Canada, 04 October 2018

MaRS Innovation announced today the second project to be developed under their LAB150 partnership with Evotec. The project aims to develop a novel therapeutic approach to treat glaucoma, an irreversible neurodegenerative disease of the optic nerve which can lead to blindness. This project is derived from a decade of research investigating the molecular pathways underlying tissue damage and repair in the eye in the laboratory of Dr. Jeremy Sivak, Senior Scientist at UHN’s Krembil Research Institute, in Toronto.

Evotec publishes DDup 7 – Kidney diseases 2.0
Hamburg, Germany, 27 September 2018

In this 7th DDup issue, we delve into the unique new kidney platforms poised to change the trajectory of kidney disease research and therapeutics development.

Evotec and Almirall enter into research collaboration in the field of dermatological diseases
Hamburg, Germany, 17 September 2018

Evotec AG and  Almirall, S.A. today announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signalling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis.

Evotec and Celgene enter partnership in the field of targeted protein degradation
Hamburg, Germany, 06 September 2018

Evotec AG announced today that Evotec and Celgene Corporation (“Celgene”) have entered into a third long-term strategic drug discovery and development partnership in the field of targeted protein degradation. In this collaboration, Evotec and Celgene will leverage Evotec’s Panomics platform in order to identify drug targets which are traditionally difficult to track. Evotec’s Panomics platform applies in particular high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates on the basis of comprehensive cell biological profiles.

Evotec AG listed in MDAX
Hamburg, Germany, 06 September 2018

Evotec AG announced today that its shares will be included in the MDAX as of 24 September 2018 as announced by Deutsche Börse on 05 September 2018. This dual listing of the Evotec shares in both TecDAX and MDAX results from the rule changes regarding the inclusion of companies in the MDAX, SDAX and TecDAX.

Evotec to attend upcoming investor conferences
Hamburg, Germany, 03 September 2018

Evotec AG announced today that its management will be presenting and attending at the following conferences:

Goldman Sachs 8th Annual Biotech Symposium, London, UK

J.P. Morgan Cazenove Pan-European Small/Mid Cap Conference, London, UK

Morgan Stanley 16th Annual Global Healthcare Conference, New York, USA

Baader Investment Conference, Munich, Germany

Berenberg and Goldman Sachs Seventh German Corporate Conference, Munich, Germany

Cantor Global Healthcare Conference 2018, New York, USA

Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington's disease
Hamburg, Germany, 30 August 2018

Evotec AG today announced that CHDI Foundation, Inc. (“CHDI”) has extended its collaboration with Evotec through to 2023. Over this period, CHDI may fund up to 75 full-time scientists at Evotec. The collaboration was initiated in 2006 and has grown considerably over this period to fully utilise Evotec’s best-in-class integrated neuroscience platform. The extension of this collaboration is a further validation of Evotec’s investment in new technologies and capabilities in support of driving innovative drug discovery collaborations. 

Evotec and CENTOGENE sign global strategic partnership on drug discovery projects in rare genetic diseases
Hamburg, Germany, 27 August 2018

Evotec AG today announced that CENTOGENE AG, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, and Evotec entered into a global strategic collaboration agreement for joint drug discovery projects, developing compounds to treat rare genetic diseases.

Evotec and Novo Nordisk form strategic research alliance in diabetes and obesity
Hamburg, Germany, 22 August 2018

Evotec AG today announced a strategic alliance with Novo Nordisk to discover and develop novel small molecule therapies to treat patients suffering from diabetes and obesity as well as co morbidities such as nonalcoholic steatohepatitis (“NASH”), cardiovascular diseases, and diabetic kidney disease.

Evotec partner Haplogen enters into collaboration with Bayer
Hamburg, Germany, 14 August 2018

Evotec AG announced today that Haplogen GmbH (“Haplogen”), a Vienna-based biotechnology company and collaboration partner of Evotec, has entered into a multi-year drug discovery and development collaboration with Bayer AG to identify new therapeutics with applications in pulmonary diseases such as chronic obstructive pulmonary disease (“COPD”).

Evotec AG reports first half-year 2018 results and corporate updates
Hamburg, Germany, 09 August 2018

Evotec AG today reported financial results and corporate updates for the first half of 2018. 

Evotec AG to report first half-year 2018 results on 09 August 2018
Hamburg, Germany, 02 August 2018

Evotec AG will report its financial results for the first half of 2018 on Thursday, 09 August 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

 

Evotec repays 50% of € 140 m acquisition loan
Hamburg, Germany, 31 July 2018

Evotec AG announced today that it completes the repayment of 50% of the € 140 m debt bridge facility within the first year of being granted in context of the Aptuit acquisition in 2017. Effective August 2017, Evotec acquired Aptuit, a partner research organisation for integrated outsourced drug discovery and development, for € 253.2 m in cash. This acquisition was financed through existing cash reserves and a new € 140 m senior debt bridge facility.

Evotec receives milestone payment for start of Phase II trial in its multi-target alliance with Bayer
Hamburg, Germany, 19 July 2018

Evotec AG announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development for the treatment of chronic cough, resulting in a payment of € 4 m to Evotec.

Evotec confirm closing of transaction with Sanofi to accelerate infectious disease research and development
Hamburg, Germany, 03 July 2018

Evotec AG today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious disease research portfolio, has been successfully closed with effect from 01 July 2018. 

Evotec achieves second milestone in diabetes alliance with Sanofi
Hamburg, Germany, 25 June 2018

Evotec AG today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached its second beta cell therapy milestone, resulting in a payment of € 3 million to Evotec. This milestone was triggered after Evotec met pre-agreed critical success criteria for a potential manufacturing process for generation of human induced pluripotent stem cell (iPSC)-derived beta cells, including the demonstration of upscaling potential and suitability of the cell product for encapsulated beta cell function in diabetes models.

Resolutions of the Annual General Meeting 2018 of Evotec AG
Hamburg, Germany, 20 June 2018

Evotec AG today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2018 with the required majorities.

Evotec and Sanofi sign definitive agreement to combat infectious diseases
Hamburg, Germany, 18 June 2018

Evotec AG today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives. This successfully seals the exclusive negotiations between the two companies and completion of the required legal social process, initiated on 08 March 2018.

Evotec forms academic BRIDGE LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research Center
Hamburg, Germany, 31 May 2018

Evotec AG announced today the formation of the LAB591 academic BRIDGE with Arix Bioscience plc (“Arix”, London Stock Exchange: ARIX ) and the Fred Hutchinson Cancer Research Center (“Fred Hutch”). LAB591 aims to accelerate research discoveries at Fred Hutch and leverage these discoveries to form new companies focused on cancer and infectious disease drug development.

Evotec and Celgene expand iPSC collaboration to include additional cell lines
Hamburg, Germany, 29 May 2018

Evotec AG announced today that the Company will receive a $ 6 m payment from Celgene following Celgene’s decision to expand the collaboration to include additional cell lines. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases.

Evotec expands iPSC platform with licence from ID Pharma
Hamburg, Germany, 23 May 2018

Evotec AG today announced that it has expanded its iPSC platform through a licence agreement with ID Pharma. The non-exclusive licence enables Evotec to both work with and differentiate induced pluripotent stem cells (“iPSC”) produced with ID Pharma’s Sendai virus (“SeV”) vector technology.

Evotec and Celgene enter into strategic oncology partnership
Hamburg, Germany, 21 May 2018

Evotec AG announced today that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.

Evotec reports first quarter 2018 results and provides corporate update
Hamburg, Germany, 09 May 2018

Evotec AG today reported financial results and provided corporate updates for the first quarter of 2018.

 

Evotec and Carna Biosciences collaborate on INDiGO platform
Hamburg, Germany, 08 May 2018

Evotec AG today announced a strategic collaboration with Carna Biosciences, Incorporated (“Carna”). Carna will access Evotec’s INDiGO platform to accelerate the development of its programme CB-1763, which is being developed for the treatment of blood cancer, through to the submission of an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration.

Evotec to present at upcoming investor conferences
Hamburg, Germany, 04 May 2018

Evotec AG announced today that its management will be presenting at the Deutsche Bank 43rd Annual Health Care Conference in Boston, USA, at the Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, USA, at the Berenberg USA Conference 2018 in Tarrytown, USA, at the Jefferies 2018 Global Healthcare Conference in New York, USA, and at the dbAccess Berlin Conference in Berlin, Germany.

Evotec expands CRISPR-based technology offering with licence from ERS Genomics
Hamburg, Germany, 02 May 2018

Evotec AG today announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene editing, thereby complementing and expanding its existing service offering in the CRISPR gene editing space. The new licence from ERS Genomics Limited complements and expands Evotec’s existing CRISPR licences through the Broad Institute with gene editing technology from Emmanuelle Charpentier and others.

Evotec AG to report first quarter 2018 results on 09 May 2018
Hamburg, Germany, 02 May 2018

Evotec AG will report its financial results for the first quarter of 2018 on Wednesday, 09 May 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for the fiscal year 2018. The conference call will be held in English.

Excelling Together for the Benefit of Women Suffering from Endometriosis
Hamburg, Germany, 25 April 2018

Five years after initiating our endometriosis alliance with Bayer, we draw some very important lessons from one of our key performance-based alliances – and share our insights.

Evotec and Bayer advance third endometriosis programme into Phase I clinical development
Hamburg, Germany, 18 April 2018

Evotec AG announced today that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive condition that affects approximately 176 million women worldwide.

Evotec forms collaboration with Petra Pharma on INDiGO platform
Hamburg, Germany, 11 April 2018

Evotec AG announced today a strategic collaboration with Petra Pharma Corporation (“Petra”). Through the collaboration, Petra will access Evotec’s INDiGO platform to accelerate the development of its lead programme Petra-01, which is being developed for a range of oncological indications, through to the submission of an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration by the close of 2018.

Evotec AG fiscal year 2017 results: Leading external innovation
Hamburg, Germany, 28 March 2018

Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2017.

Evotec launches INDiGO®, a unique integrated drug development solution for accelerating early drug candidates into the clinic
Hamburg, Germany, 26 March 2018

Evotec AG has launched its accelerated drug development service INDiGO®. With the launch of INDiGO®, Evotec’s expertise and capabilities are uniquely combined under one roof to deliver better drug candidates to patients faster and more efficiently than standard industry approaches. 

Evotec AG to report fiscal year 2017 results on 28 March 2018
Hamburg, Germany, 21 March 2018

Evotec AG will report its financial results for 2017 on Wednesday, 28 March 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2018. The conference call will be held in English.

Evotec and Sanofi in exclusive talks to create an Evotec-led infectious disease open innovation R&D platform
Hamburg, Germany, and Paris, France, 08 March 2018
Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France.
Evotec to attend upcoming investor conferences
Hamburg, Germany, 07 March 2018
Evotec AG announced today that its management will be presenting at upcoming investor conferences
Novo Holdings announce launch of “REPAIR” and formation of Scientific Selection Board
Hamburg, Germany, 28 February 2018
According to a press release published today by Novo Holdings, a new fund has been launched focused on new approaches to fight against antimicrobial resistance.
Evotec and MaRS Innovation announce first funded project under LAB150 BRIDGE
Hamburg, Germany, and Toronto, Canada, 15 February 2018
Evotec AG and MaRS Innovation announced today that they have identified the first project to be developed under their LAB150 partnership.
Evotec and APEIRON achieve first milestone in immuno-oncology alliance with Sanofi
Hamburg, Germany and Vienna, Austria, 08 January 2018
Evotec AG and APEIRON Biologics AG, a company focused on cancer immunotherapy, announced today that the companies received the first milestone payment from Sanofi under a 3 party alliance signed in August 2015.
Evotec to attend upcoming investor conferences
Hamburg, Germany, 03 January 2018
Evotec AG announced today that its management will be presenting at upcoming investor conferences
2017
Evotec enters into research collaboration with CRTD to discover novel therapies for retinal diseases
Hambuirg, Germany, 13 December 2017

Evotec AG today announced that it has entered into a research collaboration with the Center for Regenerative Therapies TU Dresden ("CRTD") to discover novel small molecule candidates for retinal diseases. 

Evotec's Academic Bridge LAB282 with Oxford University celebrating one year of impact
Hamburg, Germany, 11 December 2017

Evotec AG announced today that LAB282, the £ 13 m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec, is celebrating its first year of operation after successfully accelerating 12 drug discovery and development projects at the University.

Ncardia and Evotec Entered a Licencing Agreement for Disease Modelling Using iPS Cells
Hamburg, Germany, 04 December 2017

Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced today that they entered into a global non-exclusive IP licensing agreement with Evotec

Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim
Hamburg, Germany, 01 December 2017

Evotec AG announced today that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues of EUR 2.00 m to Evotec.

Carrick Therapeutics announces first patient dosed in phase 1 clinical trial of its oral CDK7 inhibitor: CT7001
Hamburg, Germany, 21 November 2017

Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, today announced that the first patient has been dosed in the phase 1 clinical programme of CT7001

Evotec to attend upcoming investor conferences
Hamburg, Germany, 09 November 2017

Evotec AG announced today that its management will be presenting at upcoming investor conferences

Evotec AG announces first nine-month 2017 results and corporate update
Hamburg, Germany, 08 November 2017

Evotec AG today reported financial results and corporate updates for the first nine months of 2017.

Evotec joins forces with academic leaders to accelerate drug discovery in kidney diseases and build "NEPLEX"
Hamburg, Germany, 06 November 2017

Evotec AG today announced a strategic collaboration on microfluidics technology including induced pluripotent stem cell ("iPSC") differentiation with leading academic institutions in the UK and Italy to accelerate the discovery of novel drugs to treat kidney diseases.

Evotec AG to report first nine-month 2017 results on 08 November 2017
Hamburg, Germany, 02 November 2017

Evotec AG will report its financial results for the first nine months of 2017 on Wednesday, 08 November 2017. 

Evotec and Tesaro enter strategic partnership to discover novel immuno-oncology agents
Hamburg, Germany, 26 October 2017

Evotec AG and TESARO, Inc. today announced a three-year integrated drug discovery collaboration to discover and develop novel small molecule product candidates against an undisclosed immuno-oncology (IO) target. 

Evotec achieves first milestone in neurodegeneration alliance with Celgene
Hamburg, Germany, 10 October 2017

Evotec AG announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec.

Evotec invests in Exscientia to advance AI-driven drug discovery
Hamburg, Germany, 28 September 2017

Evotec AG and Exscientia Ltd ("Exscientia") today announced that Evotec has made a EUR 15 m investment to take a minority stake in Exscientia.

Evotec and MaRS Innovation establish Academic Bridge "LAB150" in Toronto
Hamburg, Germany, 14 September 2017

Evotec AG and MaRS Innovation ("MI") today announced the launch of "LAB150".

European Investment Bank supports Evotec´s Innovate strategy with € 75 m loan
Hamburg, Germany, 08 September 2017

Evotec AG and the European Investment Bank ("EIB") announced today that the EIB has granted Evotec an unsecured loan facility of up to EUR 75 m to support Evotec's Innovate strategy.

Evotec and ABIVAX enter into strategic collaboration to develop novel antiviral agents
Hamburg, Germany, 07 September 2017

Evotec AG and ABIVAX today announced a strategic collaboration to discover and develop novel treatments for multiple serious viral infectious diseases.

Evotec to attend upcoming Investor Conferences
Hamburg, Germany, 06 September 2017

Evotec AG announced today that its management will be presenting at upcoming investor conferences.

Evotec completes acquisition of Aptuit
Hamburg, Germany, 16 August 2017

Evotec AG today announced that, effective mid-August 2017, it has successfully completed the acquisition of Aptuit as announced in detail on 30 July 2017.

Evotec announces first half year 2017 results and corporate update
Hamburg, Germany, 10 August 2017

Evotec AG today reported financial results and corporate updates for the first half of 2017.

Evotec and Fraunhofer IME-SP sign strategic collaboration on iPSC technology
Hamburg, Germany, 03 August 2017

Evotec AG today announced a strategic collaboration on induced pluripotent stem cell ("iPSC") technology with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, ScreeningPort.

Evotec AG to report first half-year 2017 results on 10 August 2017
Hamburg, Germany, 03 August 2017

Evotec AG will report its financial results for the first half of 2017 on Thursday, 10 August 2017.

Evotec to acquire Aptuit, expanding leadership in external innovation
Hamburg, Germany, 30 July 2017

Evotec AG and Aptuit announced today that they have entered into a definitive agreement under which Evotec will acquire Aptuit for $ 300 m.

Evotec expands collaboration with STORM Therapeutics on its RNA epigenetic platform
Hamburg, Germany, 27 July 2017

Evotec AG announced today an integrated drug discovery collaboration with STORM Therapeutics ("STORM") to develop new small molecule epigenetic drugs for oncology and other therapeutic areas.

Evotec and Bayer advance endometriosis programme into Phase I clinical development and extend alliance
Hamburg, Germany, 24 July 2017

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has advanced a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.

Evotec received funding from IFB Hamburg to identify antibody-mediated t-cell immunotherapies
Hamburg, Germany, 06 July 2017

Evotec AG announced today that the Company has been awarded a 'Programm für Innovation' ("PROFI") grant for a period of two years from the  Hamburgische Investitions- und Förderbank

Evotec expands iPSC drug discovery leadership through strategic collaboration with Censo Biotechnologies
Hamburg, Germany, 28 June 2017

Evotec AG today announced a collaboration with Censo Biotechnologies Ltd. ("Censo") to source and provide patient-derived induced pluripotent stem cells ("iPSC") to support Evotec's broad iPSC platform.

LAB282 accelerates with second round funding
Hamburg, Germany, 22 June 2017

Evotec AG announced today that LAB282, the drug discovery BRIDGE between Oxford University, has made its second round of awards to support promising life sciences ideas emerging from the University.

Evotec announces strategic investment in Facio Therapies to support development of novel FSHD therapy
Hamburg, Germany, 20 June 2017

Evotec AG announced today that it will make a strategic investment as part of Facio Therapies' ("Facio") 2017 funding round together with Australian, European and North American members of the Facioscapulohumeral dystrophy ("FSHD") community (Total volume: EUR 4.8 m).

Evotec receives European Mediscience Award for 'Company of the Year'
Hamburg, Germany, 16 June 2017

Evotec AG was awarded the European Mediscience Award for “Company of the Year”. 

Evotec joins NURTuRE consortium to mine unique kidney disease patient biobank
Hamburg, Germany, 14 June 2017

Evotec AG today announced that it has joined the NURTuRE consortium to drive kidney disease
focused drug discovery based on patient derived-data.

Resolutions of the Annual General Meeting 2017 of Evotec AG
Hamburg, Germany, 14 June 2017

Evotec AG today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting, which took place today, with the required majority.

Forge Therapeutics and Evotec present first efficacy data for Lpxc inhibitor in uti model at ASM MICROBE 2017
Hamburg, Germany, 02 June 2017

Forge Therapeutics and Evotec present first efficacy data for Lpxc inhibitor in uti model at  ASM MICROBE 2017

Evotec receives pre-clinical milestone as part of its Endometriosis Alliance with Bayer
Hamburg, Germany, 22 May 2017

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another significant pre-clinical milestone, triggering a payment of approx. EUR 5 m to Evotec for the transition of a programme into pre-clinical development for the treatment of endometriosis.

Evotec to attend three upcoming investor conferences
Hamburg, Germany, 16 May 2017

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at upcoming investor conferences

Evotec announces first quarter results 2017 and corporate update
Hamburg, Germany, 10 May 2017

Evotec AG today reported financial results and corporate updates for the first quarter of 2017.

Evotec achieves first milestone in Diabetes alliance with Sanofi
Hamburg, Germany, 05 April 2017

Evotec AG today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached an important milestone, triggering a payment of EUR 3.0 m to Evotec, for achieving pre-clinical proof-of-concept.

Evotec´s partner Forge Therapeutics receives prestigious Carb-X research award
Hamburg, Germany, 31 March 2017

Evotec AG today announced that its partner Forge Therapeutics ("Forge") has received a research award from CARB-X (Combating Antibiotic Resistant Bacteria) of $ 8.8 m to advance its novel Gram-negative antibiotic programme targeting LpxC for the treatment of bacterial infections.

Evotec fiscal year results 2016: Leading innovation efficiency & First-in-class drug discovery
Hamburg, Germany, 28 March 2017

Evotec AG today announced its financial results and corporate updates for the fiscal year ended 31 December 2016.

Great story - Short film
Hamburg, Germany, 03 March 2017

Evotec AG and Business France today released their short film about Evotec’s research site in Toulouse, France, under the headline: “Evotec found Business in France – Great story, short film”.

Evotec AG: 'LAB282' awarded first projects
Hamburg, Germany, 21 February 2017

Evotec AG is pleased to announce that LAB282, the £ 13 m (over EUR 15 m) drug discovery partnership with Oxford University, has made its first wave of awards, backing projects targeting cardiovascular diseases and infectious diseases.

Novo A/S becomes new long-term strategic shareholder in Evotec
Hamburg, Germany, 09 February 2017

Evotec AG today announced that it resolved on a capital increase from its authorised capital against cash. Evotec will issue 13,146,019 new shares to Novo A/S (Denmark). Novo A/S is the independent holding company for the Novo Group.

Cyprotex, an Evotec company, expands into new UK facility at Alderley Park
Hamburg, Germany, 26 January 2017

Evotec AG today announced that Cyprotex, a company wholly owned by Evotec AG, has completed the relocation of its UK operations from Macclesfield to Alderley Park.

Evotec enters into an integrated drug discovery collaboration with Asahi Kasei Pharma (Japan)
Hamburg, Germany, 19 January 2017

Evotec AG today announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan.

Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics
Hamburg, Germany, 17 January 2017

Evotec AG and MaRS Innovation today announced the launch of Fibrocor Therapeutics LP ("Fibrocor"), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases. 

Haplogen´s novel antiviral target partnered with Evotec published in 'Nature'
Hamburg, Germany, 12 January 2017

Evotec AG today announced a promising research result in the field of picornaviruses published in a scientific article by Dr Thijn Brummelkamp, the co-founder of Haplogen GmbH, a biotech company based in Vienna, Austria, that develops antiviral therapeutics in a co-owned partnership with Evotec.

Evotec and Eternygen to develop novel metabolic disease therapy
Hamburg, Germany, 09 January 2017

Evotec AG announced today that it will extend its existing relationship with Eternygen GmbH ("Eternygen") by becoming an investor in addition to being a pre-clinical drug discovery partner. 

2016
Evotec and Celgene enter into drug discovery collaboration for neurodegenerative diseases
Hamburg, Germany, 15 December 2016

Evotec AG announced today that Evotec and Celgene Corporation have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases.

Evotec completes acquisition of Cyprotex PLC
Hamburg, Germany, 15 December 2016

Evotec AG today announced the successful closing of the acquisition of 100% shares in Cyprotex PLC, a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in the UK.

Evotec and Forge Therapeutics form strategic 'superbug' alliance
Hamburg, Germany, 09 December 2016

Evotec AG today announced a strategic alliance with Forge Therapeutics, Inc. ("Forge") to advance its novel Gram-negative antibiotic programme targeting "LpxC" for the treatment of bacterial infections including those caused by drug resistant 'superbugs'.

Evotec and Merck enter into agreements to collaborate on target discovery technologies
Hamburg, Germany, 30 November 2016

Evotec AG today announced the signing of a set of collaboration agreements with the life science business of Merck, which will combine Merck's portfolio of genome editing technologies with Evotec's versatile screening platforms and disease expertise.

Evotec and Oxford create novel Partnership called 'LAB282'
Hamburg, Germany, 10 November 2016

Evotec AG today announced a novel strategic partnership with the University of Oxford, Oxford University Innovation Ltd, OUI (the university's research commercialisation company) and Oxford Sciences Innovation, OSI (the world's largest IP investment company dedicated to a single university) aimed at accelerating the translation of basic biomedical research from Oxford into new therapeutics.

Evotec AG reports results of first nine months of 2016
Hamburg, Germany, 10 November 2016

Evotec AG today reported financial results and corporate updates for the first nine months of 2016.

Evotec announces its intent to acquire Cyprotex PLC
Hamburg, Germany, 26 October 2016

Evotec AG today announced that it has made an offer to acquire Cyprotex PLC ("Cyprotex", AIM: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK.

Evotec and UCB sign multi-year CNS pharmacology agreement
Hamburg, Germany, 20 October 2016

Evotec AG today announced a collaboration with UCB to provide a broad range of in vitro pharmacology services.

Evotec and Carrick Therapeutics build strategic alliance
Hamburg, Germany, 04 October 2016

Evotec AG announced today that in line with its strategy to participate in promising corporate formations it will deepen its already existing relationship with Carrick.

Evotec receives further important pre-clinical milestone in endometriosis alliance with Bayer
Hamburg, Germany, 29 September 2016

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another key pre-clinical milestone for the transition of a project from the alliance portfolio into pre-clinical development.

Evotec enters into strategic multi-target alliance with C4X Discovery
Hamburg, Germany, 28 September 2016

Evotec AG today announced a multi-target collaboration with C4X Discovery Holdings plc ("C4XD").

Evotec enters into a research collaboration with Inserm in oncology
Hamburg, Germany, 22 September 2016

Evotec AG announced today that the Company has entered into a research collaboration with Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research ("Inserm").

Evotec and Bayer partner to develop new treatments to fight kidney diseases
Hamburg, Germany, 21 September 2016

Evotec AG today announced that Evotec and Bayer have entered into a five-year, multi-target research partnership in kidney disease. 

Evotec AG reports results of first half of 2016
Hamburg, Germany, 10 August 2016

Evotec AG today reported financial results and corporate updates for the first half of 2016.

Evotec achieves clinical development milestone as part of its multi-target alliance with Bayer in endometriosis
Hamburg, Germany, 04 August 2016

Evotec AG announced today that it has reached a milestone from Bayer for the progression of a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.

Evotec awarded contract from Antibiotic Research UK to begin integrated drug discovery collaboration
Hamburg, Germany, 11 July 2016

Evotec AG announced today a collaboration with Antibiotic Research UK ("ANTRUK") to identify alternative means of treating infections that are resistant to currently available antibiotics.

Evotec enters license agreement for access to CRISPR-Cas9 gene editing technology
Hamburg, Germany, 06 July 2016

Evotec AG announced today that the Company has entered into a non-exclusive licence agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology.

Evotec and Ellersbrook join forces to accelerate TargetNASH
Hamburg, Germany, 29 June 2016

Evotec AG announced today that the investment company Ellersbrook GmbH & Co. KG, ("Ellersbrook"), Germany, will invest into Evotec's internal TargetNASH programme. 

Resolutions of the Annual General Meeting of Evotec AG
Hamburg, Germany, 14 June 2016
APPROVAL OF ALL AGENDA ITEMS WITH THE REQUIRED MAJORITYACTIONS OF MANAGEMENT BOARD AND SUPERVISORY BOARD APPROVEDAPPOINTMENT OF ERNST & YOUNG GMBH WIRTSCHAFTSPRÜFUNGSGESELLSCHAFT AS AUDITORNEW RESOLUTION AUTHORISING THE ...
Evotec receives European Mediscience Award for ‘Best Communication’
Hamburg, Germany, 10 June 2016
Hamburg, Germany, 10 June 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) was awarded the European Mediscience Award for best communication. The award was presented to Gabriele Hansen, VP Corporate ...
Evotec extends integrated drug discovery alliance with Genentech
Hamburg, Germany, 24 May 2016

Evotec AG today announced that Genentech, a member of the Roche Group, has extended its integrated drug discovery alliance with Evotec for a further three years to discover novel small molecule therapeutics.

Evotec AG reports results of first quarter 2016
Hamburg, Germany, 10 May 2016

Evotec AG today reported financial results and corporate updates for the first quarter of 2016.

Evotec to report First Quarter 2016 Results on 10 May 2016
Hamburg, Germany, 03 May 2016
Hamburg, Germany - 03 May 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) will report its financial results for the first quarter of 2016 on Tuesday, 10 May 2016. The Company is going to hold a ...
Evotec and Exscientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics
Hamburg, Germany, 26 April 2016

Evotec AG and Exscientia Ltd (Dundee, UK) today announced a collaboration with the objective to discover and develop first-in-class bispecific small molecule immuno-oncology therapies.

Evotec and Pierre Fabre sign multi-year compound management agreement
Hamburg, Germany, 19 April 2016

Evotec AG today announced a multi-year compound management agreement with Pierre Fabre Laboratories, the 2nd largest private French pharmaceutical group.

Evotec spins off auto-immune disease company as 'Topas Therapeutics GmbH'
Hamburg, Germany, 22 March 2016

Evotec AG today announced the formation of a spin-off company in the field of nanoparticle-based therapeutics to treat immunological disorders.

Evotec FY 2015: Excellent execution meets first-in-class innovation
Hamburg, Germany, 22 March 2016

Evotec AG today announced its financial results for the fiscal year ended 31 December 2015.

Evotec AG: Fiscal year 2015 results presentation on 22 March 2016
Hamburg, Germany, 15 March 2016
Hamburg, Germany - 15 March 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) will report its financial results for 2015 on Tuesday, 22 March 2016. The Company is going to hold a conference call to ...
Evotec achieves milestone in collaboration with Padlock Therapeutics
Hamburg, Germany, 10 March 2016

Evotec AG today announced the achievement of a key pre-clinical milestone in the ongoing alliance with its research partner Padlock Therapeutics, Inc. ("Padlock").

Evotec to present at IR conference
Hamburg, Germany, 03 March 2016
Hamburg, Germany - 03 March 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its CEO, Dr Werner Lanthaler, will present at the BioCapital Europe 2016 in Amsterdam, The Netherlands, ...
The preclinical clinical interface: A key to translational success in Oncology
Hamburg, Germany, 25 February 2016
Evotecs nächstes Webinar “The preclinical clinical interface: A key to translational success in Oncology” findet am Donnerstag, den 10. März 2016 um 10.00 Uhr EST / 15.00 Uhr GMT statt und wird unter anderem ...
Evotec awarded grant from The Michael J. Fox Foundation for Parkinson's Research
Hamburg, Germany, 02 February 2016

Evotec AG today announced that it has been awarded a research grant from The Michael J. Fox Foundation ("MJFF") to further develop Evotec's TargetaSN (Targetalpha-synuclein) programme for the treatment of Parkinson's disease.

Evotec achieves important milestone in TargetAD collaboration with Janssen in Alzheimer's disease
Hamburg, Germany, 12 January 2016

Evotec AG today announced the achievement of an important milestone in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. ("Janssen") for the transition of a project into further drug discovery process.

Evotec and UCB sign multi-year sample management agreement
Hamburg, Germany, 07 January 2016

Evotec AG today announced an EVT Execute collaboration aimed at providing a complete solution to UCB's global sample management requirements.

2015
Evotec and Spero Therapeutics extend collaboration to develop novel antibacterials
Hamburg, Germany, 15 December 2015

Evotec AG today announced an extension of an existing collaboration with Spero Therapeutics, based in Cambridge, Massachusetts, aimed at discovering and developing new and ground-breaking therapeutics for Gram-negative bacteria to treat serious infections and address the growing threat to global public health resulting from antibiotic resistance.

Evotec receives important pre-clinical milestones as part of its multi-target alliance with Bayer HealthCare
Hamburg, Germany, 10 December 2015

Evotec AG announced today that its multi-target collaboration with Bayer HealthCare has reached two important pre-clinical milestones for the transition of two projects from the alliance portfolio into late-stage discovery and pre-clinical development for the treatment of endometriosis.

Huntington’s disease and the hope for a treatment
Hamburg, Germany, 20 November 2015
Hamburg, Germany - 20 November 2015: Evotec announced that Charles Sabine, former Emmy-awarded NBC News journalist and a high-profile spokesman for the global Huntington’s disease community, gave a lecture on “Why ...
Evotec AG reports results of the first nine months of 2015
Hamburg, Germany, 10 November 2015
- STRONG GROWTH IN REVENUES AND PROFITS - THREE MAJOR EVT INNOVATE DEALS CONCLUDED - REVENUE GUIDANCE RAISED ON 15 SEPTEMBER 2015 Hamburg, Germany - 10 November 2015: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: ...
Evotec and Beyond Batten Disease Foundation collaborate to advance emerging therapies to fight juvenile Batten Disease
Hamburg, Germany, 20 October 2015

Evotec AG today announced an EVT Execute collaboration with Beyond Batten Disease Foundation aimed at discovering and developing new treatments for juvenile Batten disease, a rare, fatal autosomal recessive neurodegenerative disorder. 

Evotec awarded multi-year contract to manage National Cancer Institute Chemical Biology Consortium Screening Libraries Center
Hamburg, Germany, 05 October 2015

Evotec AG today announced it has entered into a multi-year compound management agreement with the U.S. National Cancer Institute, Department of Health and Human Services. 

Evotec AG increases its revenue guidance for 2015
Hamburg, Germany, 15 September 2015

Evotec AG today announced that it increases its financial guidance for the current year. 

Evotec enters into licence and collaboration agreement with Pfizer Inc. in tissue fibrosis
Hamburg, Germany, 09 September 2015

Evotec AG today announced that it has signed an agreement on a four-year research collaboration with Pfizer Inc.

Evotec publishes update of its DDup Special Edition – Drug discovery services
Hamburg, Germany, 04 September 2015
Hamburg, Germany - 04 September 2015: Evotec AG today published its updated DDup Special edition “Drug discovery services”. This new edition outlines Evotec’s drug discovery platforms including new capacities, ...
Evotec and CHDI Foundation expand ongoing collaboration to fight Huntington's disease using Evotec's expanded capabilities and footprint
Hamburg, Germany, 02 September 2015

Evotec AG today announced that CHDI Foundation, Inc. has extended and expanded its collaboration with Evotec through to August 2018.

Evotec AG reports results of first half of 2015
Hamburg, Germany, 12 August 2015

Evotec AG today reported financial results and corporate updates for the first half of 2015.

Evotec, Apeiron Biologics and Sanofi jointly develop novel small molecule-based cancer immunotherapies
Hamburg, Germany, 10 August 2015

Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, today announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies.

Sanofi and Evotec align forces to develop next generation therapies in diabetes
Hamburg, Germany, 07 August 2015

Evotec AG and Sanofi today announced a strategic collaboration in the field of diabetes.

Evotec enters innovative research initiative with Gladstone Institutes and Dolby Family Ventures in Alzheimer's Disease
Hamburg, Germany, 24 July 2015

Evotec AG today announced that it has become part of a research initiative between a newly established for-profit company of the Gladstone Institutes called Cure Network Ventures, Inc. and Dolby Family Ventures.

Evotec's partner Roche provides initial update from Phase IIb trial in Alzheimer's disease
Hamburg, Germany, 30 June 2015

Evotec AG  was updated today by its partner Roche on the initial results of the Phase IIb trial with Sembragiline, a MAO-B inhibitor for the treatment of Alzheimer's disease.

Resolutions of the Annual General Meeting of Evotec AG
Hamburg, Germany, 09 June 2015
- Approval of all agenda items with the required majority - Actions of Management Board and Supervisory Board approved - New Supervisory Board member elected: Dr Elaine Sullivan - Contingent capital for the issue of subscription ...
Evotec AG reports results of first quarter 2015
Hamburg, Germany, 12 May 2015
- VERY STRONG START TO 2015: 22% GROWTH OF GROUP REVENUES, MAINLY DRIVEN BY EVT EXECUTE - MAJOR MULTI-COMPONENT STRATEGIC ALLIANCE WITH SANOFI CLOSED- FULL-YEAR REVENUE GUIDANCE RAISED   Hamburg, Germany - 12 May 2015: ...
Facio partners with Evotec and initiates FSHD drug discovery programme
Hamburg, Germany, 29 April 2015

Evotec AG and Facio Therapies announced today that they have entered into an agreement aimed at the identification of compounds showing activity as a potential treatment to stop the progression of FSHD, a muscle wasting disease.

Asahi Kasei Pharma selects Evotec as its partner for ion channel drug discovery
Hamburg, Germany, 26 March 2015

Evotec AG today announced it has entered into a multi-target screening collaboration on several ion channel targets, with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan.

Evotec FY 2014: Strong performance in EVT Execute and acceleration of EVT Innovate
Hamburg, Germany, 24 March 2015

Evotec AG today announced its financial results for the fiscal year ended 31 December 2014.

Evotec and Sanofi sign definitive agreement for major multi-component strategic alliance
Hamburg, Germany, 20 March 2015

Evotec AG today announced that a definitive agreement for a major multi-component strategic alliance over the next five years has been signed with Sanofi.

Second Genome and Evotec to collaborate in microbiome discovery and development
Hamburg, Germany, 13 March 2015

Evotec AG and Second Genome, Inc. today announced a collaboration in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases.

Evotec and C4XD enter collaboration to identify pre-clinical development candidates for stress-related addictive disorder programme
Hamburg, Germany, 19 January 2015

Evotec AG today announced a research collaboration with C4X Discovery Holdings plc to optimise Orexin-1 selective inhibitors discovered through C4XD's unique NMR technology.

Evotec achieves further milestones in TargetAD collaboration with Janssen
Hamburg, Germany, 15 January 2015

Evotec AG today announced the achievement of several small, but very important milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the identification and selection of novel targets from Evotec's TargetAD database and for the transition of targets into the drug discovery process.

Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration
Hamburg, Germany, 07 January 2015

Evotec AG and Padlock Therapeutics, Inc. announced today that they have successfully completed an initial goal in a programme focused on developing inhibitors of protein-arginine deiminases and have further extended the collaboration that was first signed in January 2014.

2014
Evotec and Ohio State to collaborate on novel cancer therapy
Hamburg, Germany, 22 December 2014

Evotec AG today announced a research collaboration with the laboratories of Prof. Roger Briesewitz at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

Achievement of multiple milestones in Evotec's drug discovery alliances
Hamburg, Germany, 18 December 2014

Evotec AG disclosed today that it achieved multiple milestones in ongoing alliances with its strategic research partners.

Evotec and Sanofi enter into exclusive negotiations for a major multi-component strategic collaboration
Hamburg, Germany, 02 December 2014

Evotec AG announced today that it has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years.

Evotec reports results of the first nine months of 2014
Hamburg, Germany, 12 November 2014

Evotec AG today reported financial results and corporate updates for the first nine months of 2014.

Evotec receives milestone as part of its multi-target alliance with Bayer HealthCare
Hamburg, Germany, 30 September 2014

Evotec AG announced today that its multi-target collaboration with Bayer HealthCare has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis.

Evotec and its partners awarded public grants to develop new drug candidates to treat multiple sclerosis
Hamburg, Germany, 24 September 2014

Evotec AG announced today that it has entered into three novel research projects for the treatment of Multiple Sclerosis supported by research funds from the German Federal Ministry of Education and Research.

Evotec takes legal steps against Andromeda Biotech, Ltd.
Hamburg, Germany, 18 September 2014

Evotec AG announced today after careful evaluation that it will take legal steps against Israel-based Andromeda Biotech, Ltd. to recover all Evotec claims and potential damages that result from recent incidents in relation to DiaPep277®.

Evotec and the Jain Foundation expand collaboration: Start of multiple drug screening programmes
Hamburg, Germany, 15 September 2014

Evotec AG and the Jain Foundation Inc. today announced that they have further extended and expanded the collaboration first signed in 2012 and extended last year.

Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington's disease
Hamburg, Germany, 11 September 2014

Evotec AG today announced that CHDI Foundation, Inc. has extended and restated its collaboration with Evotec through 2017.

Evotec announces update on DiaPep277®
Hamburg, Germany, 08 September 2014

Evotec AG was informed that US company Hyperion Therapeutics, Inc. is terminating the development of DiaPep277® for newly diagnosed Type 1 diabetes.

Evotec’s motor neuron research team and members of the Management Board help raise awareness for ALS disease
Hamburg, Germany, 25 August 2014

On Friday, the motor neuron research group took on the ALS Ice Bucket Challenge to help raise awareness for this rapidly progressive neurodegenerative disease.

Evotec and Medicines For Malaria Venture announce a long-term compound management collaboration
Hamburg, Germany, 19 August 2014

Evotec AG today announced the start of a multi-year compound management agreement between Evotec (US) Inc. and Medicines for Malaria Venture in support of MMV's Malaria and Pathogen Box initiatives.

Evotec AG reports results of first half of 2014
Hamburg, Germany, 12 August 2014

Evotec AG today reported financial results and corporate updates for the first half of 2014.

Evotec receives first milestones in TargetAD collaboration
Hamburg, Germany, 30 July 2014

Evotec AG today announced the successful achievement of the first milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the identification and selection of three selected targets from the TargetAD database.

Evotec publishes DDup 5 – Antibiotics
Hamburg, Germany, 24 July 2014

Evotec AG today announced the publication of its fifth DDup edition.

Evotec to collaborate with Fraunhofer in joint drug discovery programmes
Hamburg, Germany, 08 July 2014

Evotec AG announced today an exclusive strategic collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in several disease areas through the combination of the relevant platforms of both organisations for internal and external drug discovery projects.

Evotec receives European Mediscience Award for ‘Best Communication’
Hamburg, Germany, 23 June 2014

Evotec AG was awarded the European Mediscience Award for best communication at a celebratory dinner on Thursday, 19 June 2014, in London. 

Evotec receives milestone payment as part of its discovery alliance with Boehringer Ingelheim
Hamburg, Germany, 19 June 2014

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 1.0 m to Evotec.

Resolutions of the Annual General Meeting of Evotec AG
Hamburg, Germany, 17 June 2014

Evotec AG today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting.

Evotec to establish an anti-infectives platform with the acquisition of Euprotec Ltd
Hamburg, Germany, 28 May 2014

Evotec AG today announced the acquisition of all shares in Euprotec Ltd, a UK-based specialist contract research organisation.

Evotec AG reports results of first quarter 2014
Hamburg, Germany, 14 May 2014

Evotec AG today reported financial results and corporate updates for the first quarter of 2014.

Evotec and Eternygen enter collaboration to identify and develop novel metabolic disease therapy
Hamburg, Germany, 06 May 2014

Evotec AG and Eternygen GmbH, a privately owned biopharmaceutical company, today announced a drug discovery collaboration to develop novel small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec's technology platform and broad expertise in drug discovery and pre-clinical development.

Evotec receives first milestone in Roche biomarker collaboration
Hamburg, Germany, 24 April 2014

Evotec AG today announced the successful achievement of a milestone in its biomarker alliance with Roche.

Evotec and Debiopharm Group(TM) to collaborate on development of new treatment for cancer
Hamburg, Germany, 02 April 2014

Evotec AG announced today a research collaboration and licensing deal with Debiopharm GroupTM Lausanne, Switzerland.

Evotec and Convergence form integrated pain alliance
Hamburg, Germany, 31 March 2014

Evotec AG today announced that it has entered into a research alliance with Panion Ltd, a subsidiary of Convergence Pharmaceuticals Holdings Ltd. Convergence is a UK company focused on the development of novel, high value analgesics to treat chronic pain.

Evotec FY 2013: Execute on Innovate to create value
Hamburg, Germany, 25 March 2014

Evotec AG today announced its financial results for the fiscal year ended 31 December 2013, which are in line with the revised expectations communicated in the fourth quarter 2013.

Evotec acquires Bionamics GmbH to accelerate 'EVT Innovate' strategy
Hamburg, Germany, 24 March 2014

Evotec AG today announced the acquisition of the Germany-based Bionamics GmbH.

2013
Evotec and Yale University to collaborate on cancer therapy
Hamburg, Germany, 17 December 2013

Evotec AG today announced a research collaboration, TargetDBR (DNA Break Repair), with the laboratories of Prof. Peter Glazer and Prof. Ranjit Bindra at Yale School of Medicine.

Evotec AG: Results of pre-clinical studies lead to reduction in revenues, nevertheless profitable and more than € 90 m cash for 2013 confirmed
Hamburg, 13 December 2013

Evotec AG today announced that it is adjusting its guidance regarding Group revenues.

Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim
Hamburg, Germany, 10 December 2013

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in November triggering revenues of € 4.0 m to Evotec.

Evotec AG reports first nine months 2013 results
Hamburg, Germany, 12 November 2013

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today reported financial results and corporate updates for the third quarter and first nine months of 2013 ending 30 September 2013.

Evotec announces TargetAD collaboration with Johnson & Johnson Innovation to identify and develop novel Alzheimer's disease therapies
Hamburg, Germany, 08 November 2013

Evotec AG today announced a collaboration with the Johnson & Johnson Innovation Center in California to identify new targets for Alzheimer's disease drug discovery and development.

Evotec and The Leukemia & Lymphoma Society enter into a strategic research collaboration
Hamburg, Germany, 05 November 2013

Evotec AG announced today that it has entered into an integrated research collaboration with The Leukemia & Lymphoma Society. 

Evotec achieves first milestones in multi-target deal with UCB
Hamburg, Germany, 28 October 2013

Evotec AG today announced that it has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with UCB in the field of immunology.

Evotec enters integrated alliance with AstraZeneca in kidney disease
Hamburg, Germany, 21 October 2013

Evotec AG today announced that it has signed an agreement with AstraZeneca in the field of kidney diseases.

Evotec publishes DDup 4 – Epigenetics
Hamburg, Germany, 18 October 2013

Evotec AG today announced the publication of its fourth DDup edition.

Evotec to hold R&D Day 2013
Hamburg, Germany, 16 October 2013

Evotec AG announced today that its R&D Day 2013 will take place on 22 October 2013 in New York City, USA. 

Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim
Hamburg, Germany, 15 October 2013

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of EUR 4.0 m to Evotec.

Evotec and Harvard University to collaborate on exploration of enteroendocrine signals affecting key metabolic pathways
Hamburg, Germany, 10 October 2013

Evotec AG today announced a second research collaboration, TargetEEM, with the laboratory of Doug Melton, Xander University Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Harvard Stem Cell Institute Scientific Co-Director and Howard Hughes Medical Institute Investigator.

Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim
Hamburg, Germany, 30 September 2013

Evotec AG  today announced that its research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of € 2.0 m to Evotec.

Evotec publishes DDup Special Edition – Drug Discovery Services
Hamburg, Germany, 18 September 2013

Evotec AG announces today the publication of a DDup Special Edition, which focuses on its drug discovery service offering.

Evotec and Harvard Stem Cell Institute form CureMN collaboration to advance ALS research
Hamburg, Germany, 12 September 2013

Evotec AG today announced a strategic partnership with the Harvard Stem Cell Institute to identify compounds that prevent or slow down the loss of motor neurons, which is characteristic of the human disease amyotrophic lateral sclerosis.

Evotec raises EUR 30 m from Biotechnology Value Fund
Hamburg, Germany, 31 August 2013

Evotec AG today announced a 9.9% increase of its share capital. 

Evotec and the Jain Foundation announce extension of research collaboration in skeletal muscular dystrophy diseases
Hamburg, Germany, 21 August 2013

Evotec AG and the Jain Foundation today announced that they have extended and expanded their research collaboration leveraging Evotec's assay development and screening capabilities to support the Jain Foundation's goals of understanding and curing dysferlinopathy.

Evotec AG reports H1 2013 results
Hamburg, Germany, 08 August 2013

Evotec AG today reported financial results and corporate updates for the first half of 2013.

Evotec and Dow AgroSciences announce collaboration on Cellular Target Profiling
Hamburg, Germany, 09 July 2013

Evotec AG today announced that Evotec and Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, have entered into a research collaboration with the objective of leveraging Evotec's advanced chemical proteomics services to support compounds in development at Dow AgroSciences.

Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim
Hamburg, Germany, 08 July 2013

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in June triggering revenues of EUR 1.5 m to Evotec.

Evotec to realign Discovery Chemistry Operations
Hamburg, Germany, 08 July 2013

Evotec AG today announced that it will close its Chemistry Operations in Thane, India.

Resolutions of the Annual General Meeting of Evotec AG
Hamburg, Germany, 12 June 2013

Shareholders of Evotec AG today approved the actions of the members of the Management Board and the Supervisory Board for the fiscal year 2012 at the Annual General Meeting.

Evotec and Harvard University to collaborate on development of new class of antibacterials
Hamburg, Germany, 16 May 2013

Evotec AG today announced a research collaboration with Harvard University aimed at discovering and developing novel anti-bacterial agents based on a highly validated target family involved in bacterial cell wall biosynthesis.

Evotec Q1 2013: Driving Innovation Efficiency
Hamburg, Germany, 14 May 2013
Revenues without milestones increased in the first quarter of 2013 by 5% compared to the first quarter of 2012- Q1 2013 revenues amounted to EUR 17.1 m (2012: EUR 20.1 m); up 5% compared to Q1 2012 revenues of EUR 16.2 m on a ...
Dana-Farber's Belfer Institute for Applied Cancer Science and Evotec establish collaboration in oncology
Hamburg, Germany, 30 April 2013

The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG today announced a research collaboration aimed at discovering and commercialising novel cancer treatments based on epigenetic drug mechanisms.

Evotec expands compound management capability to East Coast of the United States
Hamburg, Germany, 29 April 2013

Evotec AG today announced that Evotec (US) Inc. has executed a multi-year lease on a facility specifically designed to expand the offering of its Compound Management Services on the East Coast of the United States.

New hormone to treat diabetes published in 'Cell'
Hamburg, Germany, 26 April 2013

Evotec AG today announced an auspicious step in research from Harvard University.

Evotec extends drug discovery alliance with Genentech
Hamburg, Germany, 22 April 2013

Evotec AG today announced that it has extended its drug discovery alliance with Genentech, a member of the Roche Group, for three additional years.

Forward step by step with Action Plan 2016 - Continued revenue growth - Significant pipeline progress
Hamburg, Germany, 26 March 2013

Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2012.

Corporate Update
Hamburg, Germany, 18 March 2013

Evotec AG today announced that Dr Werner Lanthaler, Chief Executive Officer of Evotec, will resume his role as Chief Executive Officer of the Company with immediate effect after a period of leave due to health reasons.

Evotec achieves milestone in drug discovery collaboration with Ono Pharmaceutical Co., Ltd.
Hamburg, Germany, 11 January 2013

Evotec AG today announced that a compound identified and optimised in a research collaboration with Ono Pharmaceutical Co., Ltd. has been nominated to enter pre-clinical development, leading to the payment of an agreed milestone.

Evotec and Yale University form Open Innovation Alliance
Hamburg, Germany, 09 January 2013

Evotec AG today announced that it has entered into a strategic partnership with Yale University.

Evotec expands collaboration with MedImmune, receives milestone payment
Hamburg, Germany, 07 January 2013

Evotec AG today announced that it has expanded the scope of its collaboration with MedImmune, the global biologics arm of AstraZeneca, after hitting a key milestone.

Evotec acquires Cell Culture Service GmbH
Hamburg, Germany, 03 January 2013

Evotec AG today announced the acquisition of all shares in Cell Culture Service GmbH, a Hamburg-based company which supports the cell culture needs of a world-wide customer base of biotech and Pharmaceutical companies.

Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy
Hamburg, Germany, 02 January 2013

Evotec AG today announced that Evotec and Apeiron Biologics have entered into a research collaboration with the objective of developing immunomodulatory lead compounds for the treatment of cancer.

2012
Evotec announces NMDA antagonist license agreement
Hamburg, Germany, 17 December 2012

Evotec AG today announced that it has entered into a license agreement with Janssen Pharmaceuticals, Inc. regarding its NR2B subtype selective NMDA-antagonist portfolio for development against diseases in the field of depression.

Evotec enters biology collaboration with Probiodrug
Hamburg, Germany, 28 November 2012

Evotec AG announced today that it has entered into a collaboration with Probiodrug AG, a privately owned biopharmaceutical company focused on the development of innovative drugs for the treatment of major age related diseases.

Evotec Receives CIR (French Research Tax Credit) Accreditation
Hamburg, Germany, 23 November 2012

Evotec AG today announced that it has received CIR accreditation for a three-year period from the French Ministry of Higher Education and Research.

Evotec partners with Haplogen to develop drugs for infectious diseases
Hamburg, Germany, 15 November 2012

Evotec AG and Haplogen GmbH have signed a collaboration agreement to discover and develop small molecules against viral infectious diseases.

Evotec reports 8% revenue growth and a positive operating result of EUR2.9 m in the first nine months of 2012
Hamburg, Germany, 08 November 2012

Evotec AG today reported financial results and corporate updates for the third quarter and first nine months of 2012 ending 30 September 2012.

Evotec extends ongoing collaboration with CHDI Foundation
Hamburg, Germany, 29 October 2012

Evotec AG today announced that CHDI Foundation, Inc., a privately-funded not-for-profit research organisation dedicated to developing therapies for Huntington's disease, has extended its collaboration with Evotec until the end of 2015.

Evotec CEO awarded 'Turnarounder of the Year 2012'
Hamburg, Germany, 29 October 2012

Evotec AG announced today that Dr Werner Lanthaler, Chief Executive Officer of Evotec, was awarded the prize 'Turnarounder of the Year 2012'.

Evotec receives Milestone in Drug Discovery Collaboration
Hamburg, Germany, 08 October 2012

Evotec AG  today announced that it has received a pre-clinical milestone from its Drug Discovery Collaboration with Novartis.

Corporate Update
Hamburg, Germany, 04 October 2012

Evotec AG today announced that Dr Werner Lanthaler, CEO of Evotec, will temporarily stand down from his role within the company due to health reasons.

Multi-target alliance with Bayer
Hamburg, Germany, 01 October 2012

Evotec AG today announced that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.

Evotec and Aspireo enter into strategic advisory agreement
Hamburg, Germany, 28 September 2012

Evotec AG and Aspireo Pharmaceuticals Limited an Israeli biopharmaceutical company focused on the development of a novel somatostatin analogue, announced today that they have entered into a strategic advisory agreement for support in the development and partnering of Aspireo's Somatoprim.

Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
Hamburg, Germany, 26 September 2012

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.5 million to Evotec.

NIH awards major contract to Evotec to Manage and Operate a Small Molecule Repository
Hamburg, Germany, 19 September 2012

Evotec AG today announced that Evotec has entered into a multi-year compound management agreement with the National Institutes of Health, Department of Health and Human Services, for the operation of a Small Molecule Repository.

Building innovation on the back of profitable growth
Hamburg, Germany, 08 August 2012

Evotec AG today reported financial results and corporate updates for the second quarter and first half of 2012 ending 30 June 2012.

CureBeta, a collaboration between Evotec and Harvard University enters strategic alliance with Janssen Pharmaceuticals
Hamburg, Germany, 10 July 2012

Evotec AG today announced that it has licensed to Janssen Pharmaceuticals, Inc. a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells. 

Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received
Hamburg, Germany, 05 June 2012

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 4.0 million to Evotec.

Evotec Becomes the First Contract Research Facility in Europe to Offer Agilent's RapidFire/MS Screening for Pharmaceutical Drug Discovery
Hamburg, Germany, 16 May 2012

Evotec AG is proud to announce the addition of Agilent Technologies' RapidFire Mass Spectrometry analysis capabilities to their High Throughput Screening facilities in Hamburg.

Evotec reports continued strong revenue growth in Q1 2012
Hamburg, Germany, 10 May 2012

Evotec AG today reported financial results and corporate updates for the first quarter of 2012.

Evotec AG and 4-Antibody AG form strategic collaboration to innovate antibody selection
Hamburg, Germany, 09 May 2012

Evotec AG and 4-Antibody AG today announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service.

Evotec AG announces multi-year agreement with The United States Environmental Protection Agency (EPA)
Hamburg, Germany, 03 May 2012

Evotec AG today announced that Evotec has entered into a multi-year compound management agreement with the United States EPA. 

Evotec grants exclusive rights on EVT 401 in China to Conba Pharmaceutical
Hamburg, Germany, 02 May 2012

Evotec AG and Conba Pharmaceutical Co., Ltd. announced today the grant of a development and marketing license on EVT 401, a selective, small molecule P2X7 antagonist, for human indications with exception of ophthalmological, chronic obstructive pulmonary disease and endometriosis in China.

Evotec and Active Biotech Extend and Expand Medicinal Chemistry Collaboration
Hamburg, Germany, 26 April 2012

Evotec AG today announced that it has extended and expanded its medicinal chemistry collaboration with Active Biotech AB, to further advance an existing programme, which has entered the lead optimisation phase.

Evotec publishes DDup 2 – neurodegenerative diseases
Hamburg, Germany, 24 April 2012

Evotec AG today announced the publication of its second edition of DDup, which focuses on neurodegeneration diseases, major disorders with inadequate standards of care. 

Evotec FY 2011: Significant Growth and Focused Investments Drive Profitability and Innovation
Hamburg, Germany, 20 March 2012

Evotec AG today reported financial results and corporate updates for the year ended 31 December 2011.

Evotec and IR Pharma Establish Drug Discovery Alliance in the Field of Respiratory
Hamburg, Germany, 16 February 2012

Evotec AG and IR Pharma today announced that they have entered into an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of Respiratory Diseases.

Squeeze-out process for DeveloGen completed
Hamburg, Germany, 24 January 2012

Evotec AG today announced the completion of the squeeze-out process to acquire all of the remaining shares of DeveloGen AG from its minority shareholders.

Evotec and Harvard University Expand Strategic Alliance into Kidney Disease
Hamburg, Germany, 17 January 2012

Evotec AG today announced a second strategic alliance with Harvard University, this time including Brigham and Women's Hospital aimed at discovering and developing new biomarkers and treatments in the field of kidney disease.

Evotec Receives 4th Milestone Payment in 2011 as Part of its Discovery Alliance with Boehringer Ingelheim
Hamburg, Germany, 11 January 2012

Evotec AG today announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 2.5 million to Evotec.

2011
Nine months results: Upside materialising
Hamburg, Germany, 10 November 2011

Evotec AG today reported financial results and corporate updates for the first nine months of 2011.

Two Milestones in Fragment-based Drug Discovery Alliance with Shionogi achieved
Hamburg, Germany, 27 October 2011

Evotec AG today announced the achievement of specific success criteria in a multiple target drug discovery collaboration with Shionogi & Co Ltd. and the receipt of two milestone payments.

Evotec and APEIRON Biologics start next project on the Cbl-b target
Hamburg, Germany, 20 October 2011

 Evotec AG and Apeiron Biologics AG today announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy.

Second multi-target collaboration with UCB announced
Hamburg, Germany, 05 October 2011

Evotec AG today announced that it has entered into a second multi year, multi target integrated drug discovery collaboration with UCB in the field of immunology.

Acquisition of remaining 30% of Indian Joint Venture from DIL
Hamburg, Germany, 29 September 2011

Evotec AG today announced that it has signed a Share Purchase Agreement to acquire the remaining 30% of equity of its Joint Venture with DIL Limited, India for €1.7M.

Evotec and Roche agree to develop compound that could slow the progression of Alzheimer's disease
Hamburg, Germany, 05 September 2011

Evotec AG and Roche AG announced today that they have entered into an exclusive worldwide agreement for the development and commercialization of Evotec's MAO-B inhibitor in patients with Alzheimer's disease.

Pre-clinical Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received
Hamburg, Germany, 18 August 2011

Evotec AG  today announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 4 million to Evotec.

P2X7 antagonist programme, EVT 401, to a top tier global animal health company partnered
Hamburg, Germany, 11 August 2011

Evotec AG today announced that it has entered into a world-wide license and collaboration agreement with a top tier animal health company that intends to develop the proprietary Evotec compound EVT401, a selective, small molecule P2X7 antagonist, in the companion animal market.

Evotec reports 34% revenue and profitable earnings growth; revenue guidance raised
Hamburg, Germany, 11 August 2011

Evotec AG today reported financial results and corporate updates for the first half of 2011.

Multi-target collaboration with UCB in neurodegenerative and neurological diseases announced
Hamburg, Germany, 07 July 2011

Evotec AG today announced that it has entered into a three year integrated drug discovery collaboration with UCB to identify small molecule modulators of priority biological targets, selected by UCB, involved in CNS disorders.

Milestone in an Ion Channel Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. achieved
Hamburg, Germany, 27 June 2011

Evotec AG today announced the achievement of specific success criteria in an ion channel research collaboration with Ono Pharmaceutical Co., Ltd. and the receipt of a milestone payment. 

Evotec and Roche to jointly develop biomarkers in oncology
Hamburg, Germany, 24 June 2011

Evotec AG and Roche today announced a collaboration in novel protein-activity based biomarkers for Roche's oncology drugs under development.

Medicinal Chemistry Collaboration with Active Biotech
Hamburg, Germany, 06 June 2011

Evotec AG today announced that it has entered into a medicinal chemistry collaboration with Active Biotech AB, following the successful conclusion of a High Throughput Screening campaign to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.

Compound management business from Galapagos acquired
Hamburg, Germany, 01 June 2011

Evotec AG and Galapagos NV today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, a Galapagos Company. 

Milestone received as Boehringer Ingelheim starts Phase I clinical trial in Pain
Hamburg, Germany, 31 May 2011

Evotec AG today announced that a back-up compound in its strategic alliance with Boehringer Ingelheim has advanced into a Phase I clinical trial. Evotec will receive a milestone payment of EUR 2.0 million.

Strategic Alliance with PsychoGenics entered to Provide Integrated CNS Drug Discovery Solutions
Hamburg, Germany, 25 May 2011

Evotec AG today announced that it has entered into a strategic alliance with PsychoGenics Inc. to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies.

Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated
Hamburg, Germany, 18 May 2011

Evotec AG and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type selective NMDA antagonist EVT 101.

Evotec reports 54% Q1 revenue growth and significant expansion of drug discovery alliance business
Hamburg, Germany, 12 May 2011

Evotec AG today reported financial results and corporate updates for the first quarter of 2011.

Twelfth Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received
Hamburg, Germany, 09 May 2011

Evotec AG today announced that its research alliance with Boehringer Ingelheim has achieved a twelfth milestone triggering a payment of EUR 2.0 million to Evotec.

Acquisition of Kinaxo Biotechnologies GmbH completed
Hamburg, Germany, 19 April 2011

Evotec AG today announced that it has completed the acquisition of Kinaxo Biotechnologies GmbH, a privately held drug discovery alliance company supporting the development of targeted drugs.

Full-Year 2010 Results: A good year with a strong start into 2011
Hamburg, Germany, 24 March 2011

Evotec AG today reported financial results and corporate updates for the year ended 31 December 2010.

Evotec Establishes Research Collaboration With Harvard University and the Howard Hughes Medical Institute in Diabetes Research
Hamburg, Germany, 10 March 2011

Evotec AG today announced the establishment of a research collaboration with Harvard University and the Howard Hughes Medical Institute aimed at discovering and developing new  treatments in the field of diabetes.

Evotec to Strengthen its Compound Collection through a Collaboration with ChemBridge
Hamburg, Germany, 15 February 2011

Evotec AG today announced that it has entered into a collaboration with ChemBridge, to further enhance its screening library.

Expanding its drug discovery platform with cutting-edge technologies
Hamburg, Germany, 09 February 2011

 Evotec AG today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs.

Collaboration with Takeda Cambridge for Multi-target Hit Identification
Hamburg, Germany, 20 January 2011

Evotec AG today announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and Protease targets involved in various CNS and Metabolic diseases.

Milestone Payment received from Boehringer Ingelheim
Hamburg, Germany, 13 January 2011

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.0 million to Evotec.

Evotec deregisters from the US Securities and Exchange Commission
Hamburg, Germany, 04 January 2011

Evotec AG announced today that on 30 December 2010 it filed a Form 15F with the Securities and Exchange Commission to deregister and terminate its reporting obligations under the U.S. Securities Exchange Act of 1934 for its American Depositary Shares and its ordinary shares underlying the ADSs.

2010
Metabolic disease alliance with MedImmune
Hamburg, Germany, 15 December 2010

Evotec AG today announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune, in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells.

Collaboration on neurological disease target with Merck KGaA
Hamburg, Germany, 23 November 2010

Evotec AG today announced that it has signed within the "NEU²-Consortium" framework and partially funded by the Federal Ministry of Education and Research, an agreement with Merck KGaA, Darmstadt, Germany, to develop pre-clinical candidates for an undisclosed neurological disease.

Accelerated Positive Trend on Evotec's Revenues and Profits
Hamburg, Germany, 11 November 2010

Evotec AG today reported financial results and a corporate update for the first nine months of 2010.

License and collaboration agreement with Jingxin Pharma for EVT 201
Hamburg, Germany, 28 October 2010

Evotec AG today announced that it has entered into a license and collaboration agreement with Zhejiang Jingxin Pharmaceutical Co., Ltd for EVT 201, a novel potential treatment for insomnia.

Pain Alliance with APEIRON Biologics
Hamburg, Germany, 27 October 2010

Evotec AG today announced that it has entered into a collaboration with Apeiron Biologics AG, to initially identify small molecule modulators of DREAM, a novel target involved in perception of various pain mechanisms.

Evotec and Shionogi Enter Fragment-based Drug Discovery Alliance
Hamburg, Germany, 05 October 2010

Evotec AG today announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd., to identify small molecule modulators of various protein-protein interaction targets.

Ion Channel Hit Identification Agreement with Almirall
Hamburg, Germany, 23 September 2010

Evotec AG today announced that it has entered into a collaboration with Almirall S.A., to identify small molecule modulators of an ion channel target, selected by Almirall, involved in respiratory diseases.

Evotec Completes Acquisition of DeveloGen
Hamburg, Germany, 02 September 2010

Evotec AG today announced the Closing of the agreement to acquire DeveloGen as announced in detail on 14 July 2010.

Strong Milestone Income Leads to Profitable 1st Half
Hamburg, Germany, 12 August 2010

Evotec AG today reported financial results and corporate updates for the first half of 2010.

Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received
Hamburg, Germany, 04 August 2010

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.5 million to Evotec.

Evotec acquires DeveloGen
Hamburg, Germany, 14 July 2010

Evotec AG today announced the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company engaged in the discovery of novel therapeutic approaches for the treatment of metabolic and endocrine disorders, for up to € 14m in shares plus performance-related deferred payments.

EVT 101 Phase II study started
Hamburg, Germany, 01 July 2010

Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101.

First Milestone in Oncology Programme with Boehringer Ingelheim
Hamburg, Germany, 17 June 2010

Evotec AG today announced that it has achieved a milestone as part of its research alliance with Boehringer Ingelheim and will receive a payment of EUR 2.5 million.

Clinical Trial Milestone achieved
Hamburg, Germany, 19 May 2010

Evotec AG today announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials.

Evotec's Drug Discovery Business Set for Strong Growth
Hamburg, Germany, 12 May 2010

Evotec AG today reported financial results and corporate updates for the first quarter of 2010.

Integrated Drug Discovery Alliance with Genentech
Hamburg, Germany, 10 May 2010

Evotec AG today announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group, to discover novel small molecule therapeutics. 

Research Grant for H3 Receptor Antagonist Programme
Hamburg, Germany, 27 April 2010

Evotec AG today announced that it will receive funding of up to EUR 1.5 million from the German Federal Ministry of Education and Research to advance its H3 receptor antagonist programme into the clinic.

2009 Results: Significant Step towards Sustainability
Hamburg, Germany, 25 March 2010

Evotec AG today reported financial results and corporate updates for the year ended 31 December 2009.

M&A Advisor Global Healthcare Turnaround Company of the Year
Hamburg, Germany, 23 March 2010

Evotec AG has been named the M&A Advisor Healthcare Turnaround Company of the Year for the development and implementation of the 'Evotec 2012 - Action Plan to Focus and Grow'.

Agreement with Hypha Discovery to Further Enhance Lead Identification Platform
Hamburg, Germany, 18 March 2010

Evotec AG today announced that it has signed an agreement with Hypha Discovery Ltd. Under the terms of the agreement, Evotec will be able to provide its screening clients with access to Hypha’s MycoDiverse™ natural product collection for use as part of its hit and lead identification services.

High Throughput Screening Agreement with Active Biotech
Hamburg, Germany, 11 March 2010

Evotec AG today announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.

Good Progress in Product Development in Treatment-Resistant Depression in its Alliance with Roche
Hamburg, Germany, 10 March 2010

Evotec AG today announced two positive aspects that strengthen its integrated product development in treatment-resistant depression in its strategic alliance with Roche.

Evotec Extends and Broadens Research Agreement with Cubist Pharmaceuticals
Hamburg, Germany, 25 February 2010

Evotec AG today announced that it has extended its research agreement with Cubist Pharmaceuticals, Inc. to the end of 2010.

Evotec and Vifor Pharma Sign Major Cooperation Agreement
Hamburg, Germany, 02 February 2010

Evotec AG today announced that it has signed an agreement with Vifor Pharma. 

Evotec and CHDI Foundation, Inc. Extend Collaboration to Fight Huntington's Disease
Hamburg, Germany, 14 January 2010

Evotec AG today announced the extension of its collaboration with CHDI Foundation, Inc. through to the end of 2012.

2009
Evotec Achieves Milestone in Medicinal Chemistry Collaboration with Ono Pharmaceutical Co., Ltd.
Hamburg, Germany, 14 December 2009

Evotec AG today announced that it has received a milestone payment from Ono Pharmaceutical Co., Ltd. from its research collaboration aimed at identifying novel inhibitors for a protease target.

Evotec Wins German Government Research Grant
Hamburg, Germany, 18 November 2009

Evotec, a leading provider in the discovery and development of novel small molecule drugs, today announced that it has been granted up to € 2.5 m in research funds from the BMBF, within the Neu2 consortium, to advance research and development activities on the target Serine Racemase for potential use in neuroprotection.

Evotec Third Quarter Financial Results
Hamburg, Germany, 12 November 2009

Evotec AG today reported results and corporate updates for the third quarter and nine months ended September 30, 2009.

Evotec to Voluntarily Delist from NASDAQ
Hamburg, Germany, 10 November 2009

Evotec AG a leading provider in the discovery and development of novel small molecule drugs today announced that it plans to voluntarily delist its American Depositary Shares from the NASDAQ stock market and concentrate its share trading on the recently re-entered TecDAX platform.
 

Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration
Hamburg, Germany, 09 November 2009

Evotec AG today announced that it has extended the research collaboration with Boehringer Ingelheim for a further 4 years.

Evotec Receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim
Hamburg, Germany, 22 October 2009

Evotec AG today announced that it has achieved another milestone in its research collaboration with Boehringer Ingelheim.

Evotec Signs Agreement with DiscoveRx Corporation to Support High Throughput Screening Services
Hamburg, Germany, and Oxford, UK, 20 October 2009

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs and DiscoveRx Corporation, a premier provider of innovative cell based assay solutions, today announced a co-marketing agreement for the screening of GPCR's and other targets.

Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical Co., Ltd.
Hamburg, Germany, 15 October 2009

Evotec AG today announced that it has extended its current research collaboration with Ono Pharmaceutical Co., Ltd. and initiated a new discovery collaboration.

Evotec achieves milestone with Cardioxyl Pharmaceuticals - as compound enters the clinic
Hamburg, Germany, 01 October 2009

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced that the company has achieved an important milestone with Cardioxyl Pharmaceuticals under a collaboration agreement for the compound, CXL-1020, that has successfully moved into clinical testing.

Evotec announces Research Agreement with Biogen Idec
Hamburg, Germany, 09 September 2009

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced that it has entered into a research agreement with Biogen Idec, a leading biopharmaceutical company headquartered in Cambridge, Mass., USA.

Evotec starts Phase I with EVT 103, an NR2B-selective NMDA receptor antagonist
Hamburg, Germany, 08 September 2009

Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today the Phase I clinical study initiation for EVT 103, a small molecule NR2B-selective NMDA receptor antagonist.

Evotec completes acquisition of controlling majority stake in Research Support International Private Limited (RSIPL)
Hamburg, Germany, 31 August 2009

Evotec AG announced today that the acquisition of the controlling majority stake of Research Support International Private Limited has been successfully completed and that RSIPL is a 70%, majority owned subsidiary of Evotec as of August 31, 2009.

Evotec Announces Strong Second Quarter Financial Results
Hamburg, Germany, 07 August 2009

Evotec AG today reported results and corporate updates for the second quarter 2009.

Evotec Accelerates Growth Strategy of its Discovery Alliance Business with Acquisition of Indian RSIPL
Hamburg, Germany, 06 August 2009

Evotec AG and DIL Limited, India, announced today the signing of a definitive agreement to acquire a 70% controlling majority stake of the drug discovery service company RSIPL for EUR 2.8 million in cash, a portion of which includes a potential earn-out.
 

Evotec to Report First Half 2009 Results on August 7, 2009
Hamburg, Germany, 30 July 2009

Evotec AG will report its financial results for the first half of 2009 on Friday, August 7, 2009.
 

Evotec Receives Milestone Payment from Boehringer Ingelheim
Hamburg, Germany, 29 July 2009

Evotec AG today announced that a further research milestone, leading to payments to Evotec, has been successfully achieved in its drug discovery collaboration with Boehringer Ingelheim.

Evotec Signs High Throughput Screening Collaboration with Alios Biopharma, Inc
Hamburg, Germany, 21 July 2009

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced a collaboration with Alios Biopharma, Inc in the area of high throughput screening.

Evotec announces Research Agreement on Fragment- Based Drug Discovery with Cubist Pharmaceuticals
Hamburg, Germany, 14 July 2009

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced that it has entered into a research agreement with Cubist Pharmaceuticals, Inc., a leading acute care biopharmaceutical company located in Lexington, Mass., USA.

Evotec-RSIL Ltd extends library synthesis collaboration with Ferrer Grupo
Hamburg, Germany, 07 July 2009

Evotec-RSIL Ltd. announced today that Ferrer Grupo, the Spanish pharmaceutical and healthcare company has extended their ongoing collaboration.

Evotec Announces the Successful Completion of the First Phase I Study with EVT 401, an Oral P2X7 Receptor Antagonist - Very Good Safety Profile and Confirmed \"On Target Activity\"
Hamburg, Germany, 29 June 2009

Evotec AG today announced the successful completion of the first Phase I study with its P2X7 receptor antagonist EVT 401.

Evotec Strengthens its Ion Channel Capabilities To Support New Alliances
Hamburg, Germany, 24 June 2009

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced the expansion of its ion channel capabilities with the addition of unique, ion channel focused libraries and additional electrophysiology screening platforms. 

Evotec Announces First Quarter Results and Corporate Development Update
Hamburg, Germany, 12 May 2009

Evotec AG today reported results and corporate development updates for the first quarter ended March 31, 2009.

Evotec Acquires Zebrafish Screening Operations of Summit Corporation
Hamburg, Germany, 07 May 2009

Evotec AG today announced that the Company will acquire the zebrafish screening operations of Summit Corporation plc, including operations in Abingdon, UK, and Singapore, for £ 0.5 million in cash.

Evotec to Re-engineer Drug Discovery and Development Operations
Hamburg, Germany, 05 May 2009

Evotec AG announced today that in the context of its Evotec 2012 - Action Plan to Focus and Grow, the Company is re-engineering its drug discovery and development operations to improve efficiency and realize further cost saving potential.

Walter Wenninger Nominated for Election as New Supervisory Board Member of Evotec
Hamburg, Germany, 27 April 2009

Evotec AG announced today that the Supervisory Board proposes at the next Annual General Meeting to be held on June 4, 2009 the election of Dr Walter Wenninger as new member of the Company's Supervisory Board.

Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302
Hamburg, Germany, 14 April 2009

Evotec AG today announced the results of a Phase II proof-of-concept study investigating the potential of EVT 302, a reversible and highly selective inhibitor of monoamine oxidase B, as an aid to smoking cessation. 

Evotec Restructures and Implements \"Evotec 2012 - Action Plan to Focus and Grow\"
Hamburg, 27 March 2009

Evotec AG today announced that it will restructure to focus on core value programs and significantly reduce its operating costs.

Evotec Announces Financial Results for 2008
Hamburg, Germany, 27 March 2009

Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today reported financial results for the year ended December 31, 2008.

Evotec and Roche to Develop EVT 101 for Treatment-Resistant Depression
Hamburg, Germany, 09 March 2009

Evotec AG and Roche announced today that they have entered into an agreement for Phase II clinical development of EVT 101 in patients with treatment-resistant depression.

Evotec Appoints Dr. Werner Lanthaler as Chief Executive Officer
Hamburg, Germany, 06 March 2009

Evotec AG announced today the appointment of Dr. Werner Lanthaler as Chief Executive Officer of the Company, effective immediately.

2008
Jörn Aldag resigns as CEO of Evotec AG
Hamburg, Germany, 10 December 2008
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today that Jörn Aldag will resign from his position as President & Chief Executive Officer of Evotec. The resignation will be effective ...
Evotec Announces Three-Year Drug Discovery Collaboration
Hamburg, Germany, 03 December 2008
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today announced the start of a research collaboration with Novartis to identify and develop novel small molecule therapeutics.  The collaboration ...
Evotec Reports Strong Third Quarter 2008 and Improves Full-Year Guidance
Hamburg, Germany, 14 November 2008
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today reported results for the third quarter and nine months ended September 30, 2008.   Evotec revenues for the first nine months of 2008 were EUR ...
Evotec Earns Two Milestone Payments from Boehringer Ingelheim
Hamburg, Germany, 30 October 2008
-First compound advanced into Preclinical Development -   Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today announced that two further research milestones, leading to total payments to Evotec ...
Evotec Reports Phase I Safety Data from Tyramine Interaction Study with EVT 302
Hamburg, Germany, 27 October 2008
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today encouraging results of a Phase I safety study investigating the potential interaction of EVT 302, a reversible and highly selective ...
Evotec Announces Phase I Initiation with P2X7 Antagonist
Hamburg, Germany, 09 October 2008
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today that Phase I clinical studies for its proprietary, small molecule P2X7 receptor antagonist have been initiated.   The P2X7 receptor ...
Evotec Participates in the Sale of Direvo Biotech to Bayer Healthcare
Hamburg, Germany, 16 September 2008
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today that the Company participates via convertible bonds in the sale of Direvo Biotech AG to Bayer HealthCare AG published this morning. Evotec ...
Evotec Reports Start of Phase II Proof-of-Concept Quit Rate Study with EVT 302 and Results of Craving Study
Hamburg, Germany, 11 September 2008
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today the start of the Phase II proof-of-concept study, investigating the effect of EVT 302 on the quit rate of patients who want to stop ...
Evotec and Boehringer Ingelheim Achieve Milestone in Joint Discovery Collaboration
Hamburg, Germany, 02 September 2008
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today announced that a third milestone has been successfully achieved in their collaboration with Boehringer Ingelheim. Under the terms of the drug ...
Evotec Reports Results of the First Half of 2008
Hamburg, Germany, 06 August 2008
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today reported results for the first half of 2008.   Evotec revenues for the first half of 2008 were EUR 14.5 million, 8% below last year's level ...
Evotec Announces Initiation of Phase I Clinical Trial of VR1 Antagonist under Partnership with Pfizer Inc.
Hamburg, Germany, 01 August 2008
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today that dose escalation studies for a Phase I clinical trial of a small molecule VR1 (vanilloid receptor 1) antagonist is being progressed by ...
Dr Flemming Ornskov Nominated for Election as Chairman of the Supervisory Board of Evotec
Hamburg, Germany, 21 July 2008
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today that at its July 9, 2008 meeting the Supervisory Board of Evotec AG decided to propose the election of Dr Flemming Ornskov to the ...
Evotec's EVT 101 Well Tolerated in Four Week Higher Repeat Dose Safety Study
Hamburg, Germany, 03 July 2008
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today top-line results of a double-blind, 4-week Phase Ib study with EVT 101, an orally active NR2B-subtype selective antagonist of NMDA ...
Evotec Reports First Quarter 2008 Results
Hamburg, Germany, 08 May 2008
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) reported today results for the first quarter of 2008.   Evotec revenues for the first quarter of 2008 were EUR 7.3 million, 16% below last year's ...
Evotec Completes Acquisition of Renovis
Hamburg, Germany, 05 May 2008
Hamburg, Germany and South San Francisco, CA - Evotec AG (Frankfurt Stock Exchange: EVT) today announced that the merger has been successfully completed and that Renovis, Inc. (traded formerly on NASDAQ: RNVS) is a wholly owned ...
Evotec Completes Acquisition of Renovis
Hamburg, Germany, 02 May 2008
Hamburg, Germany and South San Francisco, CA - May 2, 2008 - Evotec AG (Frankfurt Stock Exchange: EVT) today announced that the merger has been successfully completed and that Renovis, Inc. (traded formerly on NASDAQ: RNVS) is ...
Renovis Stockholders Approve Acquisition by Evotec
Hamburg, Germany, 01 May 2008
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT) today announced that the stockholders of Renovis, Inc. (NASDAQ: RNVS) approved the adoption of the merger agreement with Evotec at a special meeting of Renovis ...
Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity during the Performance of Cognitive Tasks
Hamburg, Germany, 28 March 2008
Single-dose, volunteer fMRI study completed and reported today - Dosing in four week higher repeat dose study completed - Hamburg, Germany | Oxford, UK - Evotec (Frankfurt Stock Exchange: EVT) is pleased to announce the ...
Evotec Announces Financial Results for 2007
Hamburg, Germany, 28 March 2008
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) today reported financial results according to IFRS for the year ended December 31, 2007.   Financial results for the year were driven by strong ...
Ono Enters into a New Fragment-Based Drug Discovery Agreement with Evotec
Hamburg, Germany, 27 March 2008
Up to three-year integrated drug discovery support program - Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that the Company and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a new ...
Evotec's Registration Statement in Connection with its Proposed Acquisition of Renovis Declared Effective
Hamburg, Germany, 26 March 2008
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced today that the U.S. Securities and Exchange Commission (SEC) has declared effective Evotec's ...
Spermatech Selects Evotec as Partner for High-Throughput Screening and Lead Discovery
Hamburg, Germany, 12 March 2008
Hamburg, Germany | Oxford, UK | Oslo, Norway - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that Spermatech A/S has chosen them as a partner to identify small molecule therapeutics for their pharmaceutical discovery ...
Evotec Expands Collaboration with InterMune
Hamburg, Germany, 06 March 2008
Fragment-based drug discovery program yields results and leads to expansion of collaboration   Hamburg, Germany | Oxford, UK- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that InterMune, Inc., has signed a ...
Evotec Starts Phase II in Smoking Cessation with EVT 302
Hamburg, Germany, 28 February 2008
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Ex-change: EVT) today announced the start of its first Phase II study for EVT 302 in smoking cessation, a reversible and highly selective inhibitor of monoamine oxidase B ...
Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million
Hamburg, Germany, 14 February 2008
- Three-year extension for integrated drug discovery support in the search of novel drug candidates for the treatment of Huntington Disease   Hamburg, Germany | Oxford, UK | Los Angeles, CA, USA - Evotec AG (Frankfurt Stock ...
Phase I Safety and Tolerability Study with EVT 302 Successfully Completed
Hamburg, Germany, 07 January 2008
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) today announced that it has successfully completed a Phase I safety and tolerability study with EVT 302. The preliminary results confirm the good ...
Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
Hamburg, Germany, 07 January 2008
Registration statement on Form F-4 filed with the SEC Shares expected to be approved for listing on NASDAQ in H1 2008 Compilation of IFRS financial information resulted in adjustments of Evotec's consolidated financial ...
2007
Evotec Completes Divesture of Chemical Development
Hamburg, Germany, 03 December 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) today announced that it has completed the sale of its Chemical Development Business to Aptuit, Inc. for a total consideration of £ 31.5 million ...
Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board
Hamburg, Germany, 28 November 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) today announced that Dr Mario Polywka and Dr Klaus Maleck have been appointed to the Company's Management Board (Vorstand), as Chief Operating Officer and ...
Evotec Reports Third Quarter 2007 Results
Hamburg, Germany, 13 November 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) reported today results for the first nine months of 2007.   Highlights: Financials in-line with Evotec's full year expectations Compelling results ...
Evotec Reports Positive Top-Line Results in Phase II Study with EVT 201 in Elderly Insomniacs with Daytime Sleepiness
Hamburg, Germany, 16 October 2007
Statistical significance in primary and key secondary endpoints at both doses Data confirm robust sleep onset and sleep maintenance effects seen in the first Phase II study in the adult population Hamburg, Germany | Oxford, UK - ...
Evotec to Acquire Renovis, Seek NASDAQ Listing
Hamburg, Germany, 19 September 2007
Merger to Create Emerging Pharmaceutical Company, Broad Pipeline in Neurological and Inflammatory Diseases, Strong Cash Position   Conference call to be held at 02.00 pm CET (UK time: 01.00 pm/US: 08.00 am EDT/05.00 am ...
Evotec Sells its Chemical Development Business to Aptuit for GBP 31.5m (approx. EUR 46.4m; US$ 63.9m) in Cash
Hamburg, Germany, 11 September 2007
Evotec focuses on high-value discovery research and collaborations Chemical Development business to be integrated into global development business of Aptuit Proceeds will allow Evotec to accelerate its CNS pipeline development ...
Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia with EVT 201
Hamburg, Germany, 05 September 2007
Very robust findings on the key problems faced by insomniacs, i.e. sleep onset and sleep maintenance Evotec to host a conference call today at 11:00 am CET (10:00 am UK time, 5:00 am EST, 7:00 pm AEST) directly from the ...
European Centre for Modern Drug Discovery Established in Hamburg
Hamburg, Germany, 03 September 2007
Hamburg is on its way to becoming a leading hub of Europe's academic drug discovery, with the northern German city's town hall today announcing the foundation of European ScreeningPort GmbH, a company that will run a ...
Evotec Reports First Half 2007 Results and Business Update
Hamburg, Germany, 14 August 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) reported today results for the first half of 2007.   Highlights:  Revenues in-line with Evotec's full year expectations First proof-of-concept ...
Evotec Announces the Expansion of its GMP Sterile Pharmaceutical Manufacturing Facility
Hamburg, Germany, 17 July 2007
Hamburg, Germany | Oxford, UK | Glasgow, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today the expansion of its sterile pharmaceutical manufacturing facility in Glasgow, Scotland. The Company has doubled its capacity ...
Evotec and Research Support International Limited Announce the Formation of Evotec-RSIL Ltd, a Joint Venture for the Design, Synthesis, Management and Commercialisation of Compound Libraries
Hamburg, Germany, 11 July 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) and Research Support International Limited (RSIL), a subsidiary of DIL Ltd, announced today the formation of a joint venture in India, Evotec-RSIL Ltd, to ...
Evotec Enhances its Fragment-Based Drug Discovery Business by the Addition of NMR Screening Assets from Combinature
Hamburg, Germany, 13 June 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that it has enhanced its Fragment-Based Drug Discovery business through the acquisition of selected assets from Combinature Biopharm. ...
Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
Hamburg, Germany, 04 June 2007
Both co-primary endpoints, Wake After Sleep Onset and Total Sleep Time, and key secondary Endpoints, including Latency to Persistent Sleep, were met at both doses Evotec to host a conference call at 4pm CET (3pm UK time, 10am ...
Evotec to Launch its First Innovation Centre for Fragment Based Drug Discovery
Hamburg, Germany, 21 May 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today the launch of its Innovation Centre for Fragment Based Drug Discovery ('FBDD'). FBDD offers an alternative approach for identifying novel, ...
Evotec Reports Q1 2007 Results and Pipeline Progress
Hamburg, Germany, 10 May 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) reported a solid set of quarterly numbers today, inline with guidance for 2007.   Evotec revenues for the first quarter 2007 were EUR 15.1 million and ...
Panacos Extends Medicinal Chemistry Contract with Evotec into Fourth Year and Expands into Development Chemistry
Hamburg, Germany, 10 May 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that Panacos Pharmaceuticals, Inc. (NASDAQ: PANC) has extended its ongoing discovery collaboration with Evotec into its fourth year. ...
Evotec Announces Encouraging FY 2006 Financial Results
, 29 March 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) today reported financial results for the year ended 31 December 2006. Total Group revenues increased by 6% to €84.7m and net income improved to €-32.5m ...
Evotec Initiates its First Phase I Clinical Study with EVT 302
Hamburg, Germany, 22 March 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today the initiation of its first Phase I study with EVT 302. This open-label study is designed to access the occupancy of the monoamine oxidase ...
Evotec and Boehringer Ingelheim Enter into Target Discovery Collaboration in Alzheimer's Disease
Hamburg, Germany, 19 March 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) today announced a multi-year collaboration with Boehringer Ingelheim to jointly identify novel targets as potential points of intervention in the treatment ...
Evotec and Interprotein Sign Collaboration Agreement to Develop Interleukin 6 Inhibitors to Treat Inflammatory Diseases
Hamburg, Germany, 28 February 2007
Hamburg, Germany | Oxford, UK | Amagasaki-City, Japan - Evotec AG (Frankfurt Stock Exchange: EVT) and Interprotein Corporation (previously IntercytoNanoScience Co., Ltd.) proudly announce today that they have signed a ...
Evotec Wins Key Contracts with Solvay Pharmaceuticals: Fragment-Based Drug Discovery and a Third Extension of the Library Synthesis and Medicinal Chemistry Collaboration
Hamburg, Germany, 22 January 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announced the signing of two contracts with Solvay Pharmaceuticals, a member of the Solvay group specialising in global pharmaceutical R&D, ...
2006
PerkinElmer to Acquire Evotec Technologies
Hamburg, Germany, 01 December 2006
Focuses Evotec on core business drug discovery and development   Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) yesterday evening announced that PerkinElmer Inc. (NYSE: PKI) signed a ...
Evotec Initiates Second Phase II Clinical Trial with Insomnia Drug EVT 201
Hamburg, Germany, 17 November 2006
Study in elderly patients with primary insomnia and daytime sleepiness   Hamburg, Germany | Oxford, England - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announced today the initiation of a second Phase II study ...
Evotec Reports Strong Q3 Growth
Hamburg, Germany, 09 November 2006
Hamburg, Germany | Oxford, UK - Evotec AG (ISIN: DE000 5664809, EVT) today reported strong growth in revenues and profits for the third quarter 2006. Group revenues of the Hamburg-based drug discovery and development company ...
Evotec Technologies Installs plate::explorer(TM) and Opera(TM) for High Throughput Screening at the Genome Research Institute
Hamburg, Germany, 20 October 2006
Hamburg, Germany and Cincinnati, Ohio - Evotec Technologies GmbH, a supplier of innovative tools and technologies for life sciences and pharmaceutical drug discovery, the Genome Research Institute (GRI) at the University of ...
Daiichi Pharmaceutical Selects Evotec as Partner for Medicinal Chemistry and Compound Profiling
Hamburg, Germany, 16 October 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that it has signed a research collaboration agreement with Daiichi Pharmaceutical Co., Ltd. (a wholly owned subsidiary of ...
Evotec Achieves Certificate of GMP Compliance from MHRA
Hamburg, Germany, 28 September 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced it has received a Certificate of GMP Compliance from the Medicines and Healthcare Products Regulatory Agency (MHRA). This ...
Evotec Initiates Phase II Clinical Trial with EVT 201 for the Treatment of Insomnia
, 21 September 2006
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") announced today the initiation of a Phase II clinical trial with EVT 201 for the treatment of insomnia under a US IND. This US, multi-centre, ...
Evotec Appoints David Brister Chief Business Officer
Hamburg, Germany, 19 September 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announced today that David Brister has been appointed Chief Business Officer and a member of the Company's Executive Committee. In this newly ...
Evotec Discontinues EVT 301 Development Programme
Hamburg, Germany, 13 September 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today reported that during the one month safety and tolerability study with EVT 301 in young and elderly volunteers, several cases of ...
Evotec Reaches Second Milestone and Receives Success Payment in Alzheimer's Disease Collaboration with Takeda
Hamburg, Germany, 16 August 2006
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") announced today that the second milestone has been achieved in its four-year drug discovery collaboration with Takeda Pharmaceutical Company ...
Evotec Reports Encouraging Results for the First Half Year and Confirms Guidance
Hamburg, Germany, 11 August 2006
Hamburg, Germany | Oxford, UK - Evotec AG (ISIN: DE000 5664809, EVT) today reported financial results for the second quarter 2006. Revenues for the second quarter 2006 increased by 2% to EUR 18.8 million (Q2 2005: EUR 18.4 ...
CHDI Selects Evotec as Strategic Drug Discovery Partner in the Search for Huntington Disease Treatments
Hamburg, Germany, 10 August 2006
-Four contracts signed since March 2006 covering most of Evotec's drug discovery capability -   Hamburg, Germany | Oxford, UK | Los Angeles, CA, USA - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that ...
Evotec Successfully Completes Phase I for Potential Alzheimer's Disease and Neuropathic Pain Treatment, EVT 101
Hamburg, Germany, 08 August 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") today announced the successful completion of Phase I with EVT 101, an NR2B subtype-specific NMDA receptor antagonist for the treatment ...
Evotec Sells Single Molecule Detection Technology & IP Portfolio to Olympus
Hamburg, Germany, 24 July 2006
Evotec Sells Single Molecule Detection Technology & IP Portfolio to Olympus
DAC Selects Evotec as Strategic Partner for a Drug Discovery Collaboration on the HSP90 Cancer Target
Hamburg, Germany, 18 July 2006
- DAC in-licences compound intellectual property identified using Evotec's proprietary fragment screening platform -   Hamburg, Germany | Oxford, UK | Milan, Italy - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today ...
Evotec and Roche Form Global Alliance to Jointly Discover Novel Drugs
Hamburg, Germany, 21 June 2006
Hamburg, Germany | Oxford, UK | Basel, Switzerland - Roche and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30; Evotec) today announced that they have formed an alliance to jointly discover and develop compounds against a ...
Evotec Announces Positive Phase I/II Clinical Trial Results with Insomnia Treatment EVT 201
Hamburg, Germany, 08 June 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announced today top-line results of the proof-of-principle study for its GABA-A modulator EVT 201, for the treatment of insomnia. The Phase I/II ...
Evotec Announces Q1 2006 Financial Results
Hamburg, Germany, 11 May 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the first quarter 2006.   Q1 Highlights: Rapidly progressing CNS pipeline:EVT 301, a Phase I compound ...
Sankyo Selected Evotec as Assay Development and Screening Partner
Hamburg, Germany, 27 April 2006
Hamburg, Germany | Oxford, UK | Tokyo, Japan - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that Sankyo (a wholly owned subsidiary of DAIICHI SANKYO COMPANY, LIMITED) has chosen Evotec as a partner to ...
Evotec Signs Two Significant Contracts with Roche
Hamburg, Germany, 25 April 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that it signed two significant service contracts with Roche. These contracts build on the companies' long-standing relationship ...
University of Cincinnati and Cincinnati Children's Hospital Medical Center Partner with Evotec to Enhance Drug Discovery
Hamburg, Germany, 04 April 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) will partner with the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center (Cincinnati Children's) to enhance the ...
Evotec Announces Full Year 2005 Financial Results
Hamburg, Germany, 28 March 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the year ended 31 December 2005.   2005 Highlights: Rapidly progressing CNS pipeline: First ...
Evotec and Boehringer Ingelheim Achieve Second Milestone in Joint Discovery Collaboration
Hamburg, Germany, 10 March 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that the second milestone in its research collaboration with Boehringer Ingelheim has been successfully achieved. Under the ...
Evotec and Apeiron Biologics to Discover Novel Pain Therapeutics
Hamburg, Germany, 14 February 2006
Hamburg, Germany | Oxford, UK | Vienna, Austria - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) and Apeiron Biologics GmbH today announced that they have entered into a discovery collaboration to develop small molecules ...
Evotec Successfully Completes Single Ascending Dose Component of Phase I Trial with EVT 101 for Alzheimer's Disease
Hamburg, Germany, 03 February 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") today announced the successful completion of the single ascending dose component of the Phase I clinical study with EVT 101, a ...
Evotec and Boehringer Ingelheim Significantly Expand and Extend their Joint Drug Discovery Collaboration
Hamburg, Germany, 17 January 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") today announced that effective from 1 January 2006 Evotec and Boehringer Ingelheim GmbH ("Boehringer") will significantly expand their ...
Evotec Licenses Two Phase I Compounds with Disease Modifying Potential in Alzheimer's Disease
Hamburg, Germany, 09 January 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that it has signed an exclusive worldwide licensing agreement with Roche for two compounds in phase I clinical development for ...
2005
Evotec Reaches First Milestone and Receives Success Payment in Alzheimer's Disease Collaboration with Takeda
Hamburg, Germany, 06 December 2005
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") announced today that the first milestone has been achieved in its four-year drug discovery collaboration with Takeda Pharmaceutical Company Limited ...
3i has reduced its interest in Evotec to 4.1%
Hamburg, Germany, 29 November 2005
- Remaining interest to be held for the long-term -Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that the venture capital company 3i has, in the course of the current ...
Evotec Announces Initiation of Phase I Clinic Trial with EVT 101
Hamburg, Germany, 14 November 2005
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced initiation of a Phase I study with EVT 101, its  NR2B subtype selective NMDA receptor antagonist for the potential ...
Third Quarter 2005: Third consecutive quarter of strong services performance and first compound in Phase I clinical trials
Hamburg, Germany, 09 November 2005
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the third quarter and the nine months to the end of September 2005.   Highlights: Development of a ...
Boehringer Ingelheim Extends Scope of Collaboration with Evotec into Screening Services - New agreements signed with Boehringer Ingelheim Germany and Canada
Hamburg, Germany, 03 November 2005
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that Boehringer Ingelheim (Boehringer) has extended the scope of its collaboration with Evotec. In addition to the substantial ...
Evotec Reports Positive Results of Repositioning Clinical Trial on CNS Compound
Hamburg, Germany, 20 October 2005
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announces today that the repositioning study of its CNS-active compound (see press release of 18 March 2005) has been completed with positive ...
ProPharma Integrated into Evotec Services Division
Hamburg, Germany, 08 September 2005
Hamburg, Germany | Oxford, UK | Glasgow, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that ProPharma Limited, its formulation subsidiary based in Glasgow, Scotland, will do business under the Evotec ...
Second Quarter 2005: Evotec Progressing as Planned
Hamburg, Germany, 11 August 2005
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the second quarter and the six months to the end of June 2005.   Highlights: Development of a ...
Procter & Gamble Selects Evotec as Provider of Pharmaceutical Discovery and Chemical Development Services
Hamburg, Germany, 25 July 2005
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) and Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company (NYSE - PG), today announced that ...
Evotec Enters into Long-Term Focused Library Agreement with Almirall - Value Exceeding EUR 2.5 m over the Two-Year Contract Period
Hamburg, Germany, 21 July 2005
Hamburg, Germany | Oxford, UK | Barcelona, Spain - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) and Almirall Prodesfarma S.A., the leading Spanish multinational company, today announced that they have entered into a ...
Evotec Names Dr Tim Tasker Executive Vice President Clinical Development and Member of the Executive Committee
Hamburg, Germany, 05 July 2005
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced the appointment of Dr Tim Tasker as Executive Vice President Clinical Development and a member of its Executive Committee. He ...
Evotec Raised EUR 28.4 Million in Capital Increase
Hamburg, Germany, 24 June 2005
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announces today that its capital increase of up to 10,457,402 new Evotec shares against contribution in cash has been fully subscripted. The ...
Evotec OAI Announces AGM Approval of Capital Increase and New Supervisory Board Structure
Hamburg, Germany, 07 June 2005
Hamburg, Germany, and Oxford, UK, 07.06.2005Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announces that at the annual shareholder meeting today the Company's shareholders approved the following agenda items which are ...
Evotec OAI Achieves First Milestone in Partnership with Boehringer Ingelheim
Hamburg, Germany, 07 June 2005
Hamburg, Germany | Oxford, UK | Ingelheim, Germany - In less than one year after the start of the three-year research collaboration between Boehringer Ingelheim and Evotec OAI (Frankfurt Stock Exchange: EVT, TecDAX 30) on ...
First Quarter 2005: Full-Year Guidance Confirmed Following Strong Q1 2005
Hamburg, Germany, 10 May 2005
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the first quarter 2005.   Financial highlights: * Revenues for the first quarter increased ...
Evotec OAI Proposes Changes to its Supervisory Board to Support the Implementation of its Strategy of Proprietary Drug Development
Hamburg, Germany, 06 May 2005
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that it intends to restructure its Supervisory Board following the acquisition of Evotec Neurosciences (ENS) in March 2005. ...
Evotec OAI Extends Global Medicinal Chemistry Agreement with Roche
Hamburg, Germany, 13 April 2005
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leader in integrated high-value-added drug discovery and development, today announced that they have extended their global discovery ...
Evotec OAI AG Report Financial Results 2004 and Guidance for 2005: Strong Q4 and Solid Outlook
Hamburg, Germany, 22 March 2005
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the year ended 31 December 2004. All figures reported today are in-line with the Company's guidance ...
Evotec Acquires ENS and Secures €47m in Cash to Develop CNS Pipeline
Hamburg, Germany, 06 March 2005
Download PDFEvotec increases focus on proprietary drug discovery and development and emphasis on cash generation in contract researchHamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT) ("Evotec" or "the ...
Evotec OAI to Provide Process Validation for AnorMED Inc. Phase III Compound, AMD 3100
Hamburg, Germany, 16 February 2005
Hamburg, Germany | Oxford, UK | Vancouver, Canada - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading provider of integrated, high-value-added drug discovery and development solutions, today announced that ...
Evotec OAI's Preliminary Results 2004: Strong Q4 Performance
Hamburg, Germany, 03 February 2005
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX30) today reported preliminary financial results for the fourth quarter and the full year 2004.   Evotec OAI exceeds its 2003 revenue and ...
Evotec OAI Appoints Mary Tanner to its Supervisory Board: New Board Member brings significant life science and investment banking expertise
Hamburg, Germany, 19 January 2005
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced the appointment of Mary C. Tanner to the Company's Supervisory Board with immediate effect.   Mary Tanner brings 22 ...
2004
Evotec Technologies provides EVOscreen® and Opera to Korea
Hamburg, Germany, 21 December 2004
Hamburg, Germany - Evotec Technologies GmbH (Evotec), a supplier of innovative tools and technologies for life sciences and pharmaceutical drug discovery, today announced the successful set-up of Evotec's ultra high throughput ...
Third Quarter 2004: On Track to Reach Updated Financial Targets
Hamburg, Germany, 11 November 2004
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the third quarter and the nine months to the end of September 2004.   Financial highlights: ...
Evotec OAI Updates Guidance for 2004 and Provides Preliminary Third Quarter Revenues
Hamburg, Germany, 20 October 2004
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announces updates on 2004 financial guidance and provides preliminary third quarter revenues.   For the first nine months of 2004 ...
Evotec Technologies and QIAGEN Demonstrate Significant Benefits of Combining High-Content Cellular Imaging Systems with RNAi Applications
Hamburg, Germany, 13 September 2004
Hamburg, Germany and Venlo, The Netherlands - Evotec Technologies GmbH and QIAGEN N.V. (Nasdaq: QGENF; Deutsche Börse: QIA, Prime Standard) today announced that they have signed an agreement to promote the benefits of ...
Evotec Neurosciences and Evotec OAI Enter into Joint Drug Discovery Collaboration with Boehringer Ingelheim to Identify GPCR Modulator-based New Medicines
Hamburg, Germany, 08 September 2004
Hamburg, Germany | Oxford, UK | Ingelheim, Germany - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) and Evotec Neurosciences GmbH today announced a three year research collaboration with Boehringer Ingelheim. The ...
Bernard Questier Leaves Management Board of Evotec OAI
Hamburg, Germany, 26 August 2004
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that by mutual agreement Bernard Questier will depart from his position as Chief Business Officer. He will pursue new ...
Seikagaku Selects Evotec OAI as Assay Development and Screening Partner
Hamburg, Germany, 11 August 2004
Hamburg, Germany | Oxford, UK | Tokyo, Japan - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and ...
Second Quarter 2004: Revenues Rebound From Q1 - Good Progress in Difficult Market Environment
Hamburg, Germany, 11 August 2004
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the second quarter and the six months to the end of June 2004.   Financial highlights: ...
Evotec OAI to Apply New Rational Drug Design Platform, EVOrationale(TM), to High Priority Research Programme from ActivBiotics
Hamburg, Germany, 29 July 2004
Hamburg, Germany | Oxford, UK | Lexington, MA, USA - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and ...
Morphochem Selects Evotec OAI as a Partner for the Chemical and Pharmaceutical Development of its Dual Action Antibiotic Oxaquin
Hamburg, Germany, 21 July 2004
Hamburg, Germany | Oxford, UK | München, Germany - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated, high-value-added drug discovery and development solutions, today announced that ...
Biogen Idec Selects Evotec OAI as a Service Provider for Process Research & Development
Hamburg, Germany, 19 July 2004
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated, high-value-added drug discovery and development solutions, today announced that Biogen Idec (Nasdaq: ...
Evotec OAI Announces Preliminary Q2 Sales Significantly Improved from Q1 2004 - On Track to Meet Full-Year Guidance
Hamburg, Germany, 12 July 2004
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today reported preliminary sales figures for the second quarter ended 30 June 2004.   The Company achieved second quarter revenues of ...
Evotec OAI Undergoes Successful FDA Inspection
Hamburg, Germany, 18 June 2004
Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated, high-value-added drug discovery and development solutions, today announced a recent successful ...
Neuronova AG Selects Evotec OAI as their Assay Development and Screening Partner
Hamburg, Germany, 14 June 2004
Hamburg, Germany | Oxfordshire, UK | Munich, Germany - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and ...
Evotec OAI Enters into Discovery Agreement with Nuvios
Hamburg, Germany, 19 May 2004
Hamburg, Germany | Oxfordshire, UK | Cambridge, MA, USA - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated, high-value-added drug discovery and development services, today announced a ...
Guilford Pharmaceuticals Selects Evotec OAI as their Assay Development and Screening Partner
Hamburg, Germany, 13 May 2004
Hamburg, Germany | Oxfordshire, UK | Baltimore, MD, USA - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the ...
Evotec OAI and Roche enter into Strategic Global Discovery Chemistry Agreement
Hamburg, Germany, 12 May 2004
Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology ...
First Quarter 2004: Delivering on Forecast and Strategy
Hamburg, Germany, 12 May 2004
Hamburg, Germany | Oxfordshire, UK - Evotec OAI (Deutsche Börse: EVT, TecDAX 30) today announced financial results for the first quarter 2004.   Financial highlights: - Q1 revenues amounted to EUR 14.4 million ...
Evotec OAI Expands ADMET Platform, EVOprofile
Hamburg, Germany, 07 May 2004
Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology ...
Evotec OAI to Expand Agreement with Oxford Bioscience Partners through Integration of its New Rational Drug Design Platform, EVOrational
Hamburg, Germany, 26 April 2004
Hamburg, Germany | Oxfordshire, UK | Boston, USA - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and ...
Evotec OAI Enters into Integrated Virtual Screening and Medicinal Chemistry Agreement with Fujisawa
Hamburg, Germany, 13 April 2004
Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology ...
Evotec Neurosciences Completes € 25 Million Series A Financing
Hamburg, Germany, 02 April 2004
Hamburg, Germany - Evotec Neurosciences (ENS), a subsidiary of Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), today announced that it has secured a € 25 million first round of venture capital financing. The ...
Evotec OAI and Panacos Enter into Medicinal Chemistry Agreement to Design and Optimise Novel Anti-HIV Compounds
Hamburg, Germany, 25 March 2004
Hamburg, Germany | Oxfordshire, UK | Gaithersburg, MD, USA - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical ...
Evotec Neurosciences to licence NMDA receptor NR2B subunit selective antagonists from Roche
Hamburg, Germany, 25 March 2004
Hamburg, Germany - Evotec Neurosciences GmbH (ENS), a subsidiary of Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), today announced that it has acquired from Roche an exclusive worldwide license to develop and market an ...
Evotec OAI AG - Financial Results 2003: Strategy delivers strong revenue growth and positive EBITDA
Hamburg, Germany, 25 March 2004
Hamburg, Germany | Oxfordshire, UK - Evotec OAI (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries, ...
Evotec OAI Announces Re-organisation of it's Executive Management to Reflect the Growing Strengths of its Core Businesses
Hamburg, Germany, 17 February 2004
Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG, (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development to the pharmaceutical and biotechnology industries, today ...
Evotec OAI's Preliminary Results 2003 Show Strong Sales Growth and Robust EBITDA Profitability
Hamburg, Germany, 16 February 2004
Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology ...
Evotec OAI and Toray Sign Integrated Medicinal Chemistry, Virtual Screening and Compound Profiling Agreement
Hamburg, Germany, 11 February 2004
Hamburg, Germany | Oxfordshire, UK | Tokyo, Japan - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, and Toray ...
Evotec OAI and Rib-X Pharmaceuticals Enter Into Medicinal Chemistry Collaboration
Hamburg, Germany, 14 January 2004
Hamburg, Germany | Oxfordshire, UK | New Haven, CT, USA - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, and Rib-X ...
2003
Third Quarter 2003: Evotec OAI Reports 9-month Revenues up 20%, Positive EBITDA Sustained
Hamburg, Germany, 12 November 2003
"This has been another excellent quarter for Evotec OAI. Despite continuing challenging market conditions and adverse currency effects, revenues continued to rise strongly and we remain firmly on track to post our first year of ...
Evotec OAI and Roche Sign Medicinal Chemistry Collaboration in Oncology
Hamburg, Germany, 22 October 2003
Roche and Evotec OAI have worked together on the production of chemical libraries since 2001, with Evotec OAI supplying chemical compound libraries to Roche for use in drug discovery screening programmes. This agreement expands ...
Evotec OAI and Biofrontera to Offer Natural Compounds for Drug Discovery Services
Hamburg, Germany, 14 October 2003
Biofrontera's huge, largely unexploited pool of natural compounds constitutes a rich source of potential drug candidates. About 140,000 subfractions, containing over 2 million compounds, are immediately available for screening ...
Evotec OAI and DeveloGen Announce a Strategic Drug Discovery and Development Alliance for Metabolic Diseases
Hamburg, Germany, 10 September 2003
This collaboration is a strategic first for both companies, where the partners share risks and rewards equally. The partnership creates an integrated venture combining DeveloGen's pipeline of over 200 primary targets and 30 ...
Second Quarter 2003: Evotec OAI Reports Positive EBITDA in First Half
Hamburg, Germany, 12 August 2003
Financial highlights:Revenues increased to EUR 34.8 m (+5%). At constant exchange rates, sales rose by 16% EBITDA positive in first half; on track for full-year sales growth of 10-15% and positive EBITDA in 2003 Operating loss ...
Evotec OAI Appoints Bernard Questier Chief Business Officer
Hamburg, Germany, 06 August 2003
Bernard Questier, 49, will join Evotec OAI with effect from 6 October 2003. Being based in the Company's headquarter in Hamburg, Germany, he will lead Evotec OAI's business development functions as a member of the Management ...
Evotec Neurosciences and Takeda enter into drug discovery alliance in Alzheimer's disease
Hamburg, Germany, 01 August 2003
ENS will grant Takeda access to its proprietary database of Alzheimer's disease-related targets, and further validate selected target candidates for downstream drug discovery programs. Takeda will make payments to Evotec ...
Evotec OAI Signs Medicinal Chemistry Agreement with Axxima Pharmaceuticals
Hamburg, Germany, 25 June 2003
Under the terms of the drug discovery contract Evotec OAI will apply its integrated medicinal chemistry platform to optimise initial screening hits already identified by Axxima and rapidly progress them towards novel clinical ...
Artesian Therapeutics Selects Evotec OAI as Drug Discovery Partner
Hamburg, Germany, 15 May 2003
Hamburg, Germany | Abingdon, UK | Gaithersburg, USA - Evotec OAI (Deutsche Börse: EVT, TecDAX 30), a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, and ...
First Quarter 2003: Evotec OAI Reports Good Start to 2003
Hamburg, Germany, 08 May 2003
Financial highlights: Revenues increased to EUR 17.8 m (+5%) although adverse currency effects had an impact on business in Q1. At constant exchange rates growth would have been +15%. Reduced SG&A and R&D expenses led ...
Evotec OAI and Novartis Pharma AG Sign Lead Discovery Collaboration
Hamburg, Germany, 10 April 2003

Joern Aldag, President and Chief Executive Officer of Evotec OAI, commented: "Following a successful collaboration in the development of our EVOscreen® uHTS system, Novartis has chosen Evotec OAI to support their lead discovery efforts. We are delighted that one of the world's leading R&D organisations has chosen our expertise in drug discovery and our technology platform in this critical area of research."

Evotec OAI AG - Financial Results 2002, Sustained Growth in Challenging Markets
Hamburg, Germany, 25 March 2003
Financial Highlights: Group Revenues EUR 70.0 million, up 11% Discovery and Development Services revenues EUR 58.6 million, up 13% EBITDA EUR (2.2) million, exceeding company October 2002 guidance (EUR (3) to (6) million); ...
British Biotech to transfer research operations to Evotec OAI
Hamburg, Germany, 21 March 2003
The principal terms of the agreement are: 17 research scientists to transfer from British Biotech to Evotec OAI; Evotec OAI to provide medicinal chemistry and biology services under contract to support British Biotech's ...
Psychiatric Genomics Selects Evotec OAI as Their Strategic Chemistry Partner for Drug Discovery and Development
Hamburg, Germany, 30 January 2003
Download PDF Hamburg, Germany | Oxford, UK | Gaithersburg, Maryland, USA - Evotec OAI AG (Deutsche Börse: EVT, Prime Standard), a partner for integrated high-value-added drug discovery services to the pharmaceutical and ...
Evotec OAI's Preliminary Results 2002: Q4 Results Exceeding Expectations
Hamburg, Germany, 30 January 2003
Hamburg, Germany | Abingdon, UK - Evotec OAI AG (Deutsche Börse: EVT, Prime Standard), a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, today reported ...
Evotec OAI to Support Dynogen Pharmaceuticals in the Discovery and Development of Novel Pharmaceuticals
Hamburg, Germany, 30 January 2003
Download PDF"Dynogen's near term strategic approach is to acquire neurological compounds which have been developed for pain, depression, anxiety or other indications and develop them for GU and GI disorders. Longer term, we plan ...
Euroscreen and Evotec OAI Partner GPCR Expertise - Companies Provide Comprehensive GPCR Screening, Product and Research Services
Hamburg, Germany, 20 January 2003
Hamburg, Germany | Abingdon, UK | Brussels, Belgium - Evotec OAI AG (Deutsche Börse: EVT, Prime Standard) and Euroscreen S.A. today announced they have exchanged know how and expertise to enhance their respective strengths ...
Evotec OAI Achieves Milestone with Clinical Advancement of Vertex Pharmaceuticals Compound
Hamburg, Germany, 16 January 2003
As part of an agreement that began in 1998, Vertex has utilised a broad range of chemistries Evotec OAI has to offer and Evotec OAI has provided compounds and compound arrays for pharmaceutical screening and lead optimisation. ...
Evotec OAI Announces Drug Discovery Agreement with KeyNeurotek and the Institute of Medical Technology Magdeburg (IMTM)
Hamburg, Germany, 14 January 2003
Under the terms of the collaboration, Evotec OAI will assist KeyNeurotek and IMTM to develop new lead structures with respect to two of their partners' proprietary targets. This program is partly supported by the ...
Evotec OAI and Oxagen Initiate Drug Discovery Alliance
Hamburg, Germany, 08 January 2003
In the search for new drugs Evotec OAI will apply its fully integrated drug discovery process know-how to express the target of interest, develop Ca2+ flux assays, screen the target against its corporate library of drug-like ...
2002
Achillion Selects Evotec OAI as Preferred Partner for Clinical Compound Manufacturing
Hamburg, Germany, 11 December 2002
Hamburg, Germany | Abingdon, UK - Evotec OAI AG (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, today announced that Achillion Pharmaceuticals, Inc. ...
Evotec OAI Names Ian Hunneyball President of Discovery Services and Member of the Management Board
Hamburg, Germany, 09 December 2002
Evotec OAI Names Ian Hunneyball President of Discovery Services and Member of the Management Board
Evotec OAI Extends Medicinal Chemistry Agreement with Avidex
Hamburg, Germany, 06 December 2002
Hamburg, Germany | Abingdon, UK - Evotec OAI AG (NM: EVT), a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, announced today that it has signed an extension to ...
Evotec OAI to Collaborate with Prolysis in the Development of New Antibiotics
Hamburg, Germany, 04 December 2002
Hamburg, Germany | Oxford, UK - Evotec OAI AG (NM: EVT), a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, and Prolysis Ltd. (Oxford, UK), a biotechnology ...
Evotec OAI: Direvo Raises EUR 10.5 Million in Series B Financing
Hamburg, Germany, 26 November 2002
Hamburg, Germany | Abingdon, UK - Evotec OAI AG (NM: EVT), a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, announced today that Direvo Biotech AG has raised ...
Evotec OAI Extends Discovery Agreement with Solvay Pharmaceuticals
Hamburg, Germany, 25 November 2002
Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, announced today a one-year ...
Elixir Pharmaceuticals to Access Broad Chemical and Biological Drug Discovery and Development Services in Agreement with Evotec OAI
Hamburg, Germany, 21 November 2002
Deal Marks First Agreement under Innovative Alliance between Evotec OAI and Oxford Bioscience Partners   Hamburg, Germany | Abingdon, UK | Cambridge, Mass., USA - Evotec OAI AG (NM: EVT), a partner for integrated ...
Third Quarter 2002: Evotec OAI Reports Solid Performance in Difficult Market Environment
Hamburg, Germany, 14 November 2002
Download PDF 9 months sales increase of 20% to EUR 47.5m, in line with company guidance Growth in Q3 of 8% lead to a more cautious outlook on sales and profit targets EBITDA slightly below last year (EUR ...
Evotec OAI Enters into Innovative Drug Discovery and Development Agreement with Venture Capital Firm Oxford Bioscience Partners
Hamburg, Germany, 14 November 2002
Download PDFHamburg, Germany | Abingdon, UK | Boston, USA - Evotec OAI AG, Hamburg, Germany (NM: EVT), a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, and ...
Evotec Technologies: EVOscreen® Mark III Successfully Passed Site Acceptance Testing at Novartis
Hamburg, Germany, 14 November 2002
Hamburg, Germany - Evotec Technologies GmbH, a subsidiary of Evotec OAI AG (Neuer Markt: EVT) providing innovative technologies for life sciences, announced today the implementation of the second ultra-high-throughput screening ...
Evotec OAI Announces Medicinal Chemistry Agreement with British Biotech
Hamburg, Germany, 07 November 2002
Download PDFHamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, announced today that ...
Evotec OAI Successfully Completes Assay Development Programme with ALTANA Pharma AG
Hamburg, Germany, 04 November 2002
Download PDF Second collaboration milestone achieved Evotec OAI's cell analyzer "Opera" to be integrated into ALTANA Pharma's drug discovery platform Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer ...
Evotec OAI Expands Long-Term Screening Technology Alliance with Pfizer
Hamburg, Germany, 31 October 2002
Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, announced today that it has ...
Evotec OAI Announces Update on Annual Guidance
Hamburg, Germany, 23 October 2002
Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT) announces third quarter revenues and an update on the company's forecast for its 2002 financial performance.   "Based on our excellent ...
Evotec Technologies Launches High-Throughput Cell Analyser 'Opera'
Hamburg, Germany, 10 October 2002
Revolution in high-content analysis of cellular events in assay development and screening Hamburg, Germany - Evotec Technologies GmbH, Hamburg, Germany, a wholly-owned subsidiary of Evotec OAI AG (Neuer Markt: EVT) providing ...
Evotec OAI Grants Licence to Roche Diagnostics
Hamburg, Germany, 22 August 2002
Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, today announced that it granted a ...
Second Quarter 2002: Evotec OAI Meeting its Growth Targets
Hamburg, Germany, 20 August 2002
Sales increase of 26% to EUR 33.2 million, in line with company guidance Net loss reduced by 82% to EUR (13.7) million EBITDA improved by 28% Cash burn significantly reduced year-on-year Strong order book ...
Evotec OAI Announces Key Management Appointments To Position For the Next Phase Of Growth
Hamburg, Germany, 25 June 2002
Dr John Kemp joins from Roche to become Chief Executive Officer of Evotec Neurosciences GmbH with responsibility for Discovery Programmes (Central Nervous System) New post of President of Discovery Services, the Company's ...
Infinity Pharmaceuticals Selects Evotec OAI as Their Assay Development and Screening Partner
Hamburg, Germany, 13 June 2002
Hamburg, Germany | Abingdon, UK | Boston, USA - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, announced today the ...
Evotec OAI and U3 Pharma Sign Screening and Drug Discovery Collaboration
Hamburg, Germany, 06 June 2002
Hamburg and Martinsried, Germany | Abingdon, UK - Evotec OAI AG (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, announced today the signing of a ...
Evotec OAI and Taisho Pharmaceutical Co., Ltd. Start Drug Discovery Collaboration
Hamburg, Germany, 22 May 2002
Hamburg, Germany | Abingdon, UK | Tokyo, Japan - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high value added drug discovery services, announced today that it has entered into a drug discovery ...
Evotec OAI AG - First Quarter 2002: Overachieved revenue goal for Q1 and strong order book for 2002
Hamburg, Germany, 15 May 2002
Sales increase of 50% to EUR 16.9 million 42% growth in drug discovery services Net loss reduced by 86% to EUR (5.7) million EBITDA of EUR (0.7) million close to break-even Cash burn significantly reduced to EUR ...
Evotec OAI Signs Contract Extension with Vertex Pharmaceuticals
Hamburg, Germany, 15 May 2002
Download PDFHamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high value added drug discovery services, announced today that it will continue to provide drug discovery ...
Evotec OAI and Novartis intensify collaboration
Hamburg, Germany, 08 May 2002
Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high value added drug discovery services, announced today that its long-term partner Novartis will acquire additional ...
Roche extends Discovery Chemistry Agreement with Evotec OAI
Hamburg, Germany, 29 April 2002
Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high value added drug discovery services, announced today the extension of its original one-year discovery chemistry ...
Evotec OAI and MediGene have Identified New Active Compounds for the Treatment of Cardiac Diseases
Hamburg, Germany, 27 March 2002
Hamburg | Martinsried, Germany " The biopharmaceutical company MediGene AG (Nmarkt/Frankfurt: MDG) and Evotec OAI (Nmarkt/Frankfurt: EVT), a supplier of integrated high-value-added drug discovery services, have successfully ...
Evotec OAI and SiREEN Enter Into A Drug Discovery and Development Agreement To Identify New Small Molecule Therapeutics
Hamburg, Germany, 25 March 2002
Hamburg, Germany | Abingdon, UK | Munich, Germany - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high value added drug discovery services, and SiREEN AG, a drug discovery and development company, ...
Evotec OAI Successfully Passes First Milestone in Collaboration with Byk Gulden/Altana
Hamburg, Germany, 25 March 2002
Hamburg, Germany | Abingdon, UK " Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value-added drug discovery services, announced today that it has successfully completed phase 1 of the ...
Evotec OAI AG - 2001 Annual Financial Statements: Continued Strong Progress and an Optimistic Outlook for 2002
Hamburg, Germany, 25 March 2002
 Sales increase of 124% to EUR 63.2 million year on year 21% pro-forma growth in drug discovery services Adjusted net loss reduced by 35% to EUR (8.1) million EBITDA of EUR (1) m close to break-even Positive ...
Evotec OAI and Ionix Collaborate on Analgesic Drug Discovery
Hamburg, Germany, 05 February 2002
Hamburg, Germany | Abingdon, UK " Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value-added drug discovery services, announced today that it has signed an agreement with Ionix ...
Evotec OAI and Serono Extend Discovery Chemistry Agreement First compounds resulting from the collaboration progressing into pre-clinical testing.
Hamburg, Germany, 24 January 2002
Hamburg, Germany/ Abingdon, UK " Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value-added drug discovery services, announced today a one year, EUR 2.4 million lead optimisation programme ...
2001
Evotec OAI EVOscreen® Mark III Passed Factory Acceptance Testing with GlaxoSmithKline with Excellent Results
Hamburg, Germany, 17 December 2001
Hamburg, Germany / Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value added drug discovery services, today announced that its new generation of ultra-high- throughput screening ...
Evotec OAI AG Signs Chemical Library Agreement with Merck & Co., Inc.
Hamburg, Germany, 03 December 2001
Hamburg, Germany/ Abingdon, UK  - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value-added drug discovery services, announced today that it has entered into an agreement with Merck & ...
Third Quarter 2001: Evotec OAI on Track for 2001
Hamburg, Germany, 08 November 2001
Sales increased to EUR 39.6 million Operating loss reduced to EUR (11.9) million Several contracts new or expanded Extraordinary strong Q4 expected Hamburg, Germany / Abingdon, UK - Evotec OAI AG (Neuer Markt: ...
Evotec OAI and Byk Gulden/Altana Enter into a Collaboration
Hamburg, Germany, 25 October 2001
Hamburg, Germany / Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value added drug discovery services, announced today a contract agreement with Byk Gulden Lomberg Chemische ...
Evotec OAI and VitaResc Biotech Extend Collaboration in Anti-Thrombotic Drug Development
Hamburg, Germany, 16 October 2001
Martinsried, Hamburg, Germany / Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value added drug discovery services, and VitaResc Biotech AG, Martinsried, Germany, announced today ...
Evotec OAI and Rigel Pharmaceuticals Enter Into Medicinal Chemistry Agreement To Identify A New Class of Anti-Cancer Compounds Called Ubiquitin Ligase Inhibitors
Hamburg, Germany, 02 October 2001
South San Francisco, California/ Hamburg, Germany/ Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value added drug discovery services, and Rigel Pharmaceuticals Inc., a drug ...
Evotec OAI Appoints Dirk Ehlers as Chief Financial Officer
Hamburg, Germany, 11 September 2001
Hamburg, Germany/ Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value added drug discovery services, today announced the appointment of Dr Dirk Horst Ehlers to the Chief ...
Evotec OAI and Novartis sign licence and technology agreement for on-bead screening
Hamburg, Germany, 04 September 2001
Hamburg, Germany/Abingdon, UK - Evotec OAI (EVOTEC BioSystems AG, Neuer Markt: EVT), a provider of high-quality integrated drug discovery services for the pharmaceutical and biotechnology industries, has entered into a licence ...
Second Quarter 2001: Evotec OAI Makes Further Good Progress
Hamburg, Germany, 21 August 2001
Sales increased significantly to EUR 26.3 million Financials in line with expectations Several contracts new or expanded Healthy cash position of EUR 35.6 million Hamburg, Germany / Abingdon, UK - EVOTEC ...
Evotec OAI Extends Combinatorial Chemistry Collaboration with Pharmacia Corporation
Hamburg, Germany, 21 August 2001
Hamburg, Germany/Abingdon, UK - Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT), a supplier of integrated high-value added drug discovery services, today announced that it has signed a new four-year contract ...
Evotec OAI Announces Appointment of Mark Whittaker as Director of Drug Discovery
Hamburg, Germany, 15 August 2001
Hamburg, Germany/ Abingdon, UK - Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT), a supplier of integrated high-value added drug discovery services, today announced that it named Mark Whittaker, D. Phil., to ...
Evotec OAI and MelTec form Joint Venture and Enter into a Drug Discovery Service Collaboration
Hamburg, Germany, 18 June 2001
Interlocking a Proteomics Target Finding and Validation Machinery with the Industrialised Drug Discovery Process: Evotec OAI and MelTec form Joint Venture and Enter into a Drug Discovery Service Collaboration Hamburg, ...
DIREVO Awarded Subsidy by North Rhine-Westphalia Government
Hamburg, Germany, 15 June 2001
Hamburg, Germany | Abingdon, UK - DIREVO Biotech AG today announced that it will receive a subsidy of DM 9.8 million from the state government of North Rhine-Westphalia. The money will be used to fund a development ...
Evotec OAI Signs a Chemical Library Contract with Roche
Hamburg, Germany, 12 June 2001
Hamburg, Germany | Abingdon, UK - Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT) a supplier of high value added biological, chemical and screening services, has signed a one-year contract to supply chemical ...
First Quarter 2001: Oxford Asymmetry (OAI) Merger Shows First Results
Hamburg, Germany, 16 May 2001
Sales increased by 440% to EUR 11.3 million Financials in line with expectations First joint biology and chemistry contracts signed Strong cash position of EUR 49.2 million Hamburg, Germany / Abingdon, UK - ...
Evotec OAI and Serono Sign Assay Development and Screening Services Agreement
Hamburg, Germany, 26 April 2001
Hamburg, Germany/ Abingdon, UK/ Geneva, Switzerland - Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT), a supplier of integrated high-value added biological, chemical and screening programmes to the ...
EVOTEC OAI: Appointment of new Chief Executive Officer
Hamburg, Germany, 18 April 2001
Hamburg, Germany | Abingdon, UK Evotec OAI today announces key management changes following the successful integration of  EVOTEC BioSystems AG and Oxford Asymmetry International.   With effect from June 30, 2001, ...
Evotec OAI Signs Technology Agreement With Celltech
Hamburg, Germany, 10 April 2001
Hamburg, Germany | Abingdon, UK - Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT), a supplier of integrated high-value added biological, chemical and screening services to the pharmaceutical and biotech ...
EVOTEC BioSystems AG - 2000 annual financial statements: Dynamic growth together with Oxford Asymmetry International
Hamburg, Germany, 29 March 2001
Sales increase by 189% to EUR 28.3 million Integration of Oxford Asymmetry International well advanced Annual results meet analyst forecasts Strong cash position of EUR 49 million First integrated service ...
MediGene applies Evotec OAIs leading technologies for the identification of novel drugs to treat cardiovascular diseases
Hamburg/Munich, 28 March 2001
Hamburg/Munich, March 28, 2001. MediGene AG (NMarkt: MDG) and EVOTEC BioSystems AG (Evotec OAI) (NMarkt: EVT) announced today, that MediGene, a biopharmaceutical company with a focus on cardiac and cancer therapies, will ...
Glaxo SmithKline Accepts EVOTEC OAI's uHTS System EVOscreen®
Hamburg, 07 March 2001
All development partners now equipped with EVOTEC OAI's ultra high-throughput screening technology:  March 7, 2001 - EVOTEC BioSystems AG (EVOTEC OAI) (Neuer Markt: EVT) today announced that EVOscreen® Mark II, the ...
EVOTEC OAI Signs Two Chemistry Services Contracts With Lilly
Hamburg, Germany/Abingdon, UK, 01 March 2001
1 March 2001 -  EVOTEC OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT), a supplier of integrated high-value added biological, chemical and screening services to the pharmaceutical and biotech industries, has ...
EVOTEC OAI Wins Contract for the Supply of Chemical Libraries to Solvay Pharmaceuticals
Hamburg, Germany/Abingdon, UK, 08 February 2001
8 February 2001 -  EVOTEC OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT), a supplier of integrated high-value added biological, chemical and screening services to the pharmaceutical and biotech industries, ...

 

Ad hoc releases

Please find below Evotec's most recent ad hoc releases according to Article 17 European Market Abuse Regulation (MAR).

 

2018
Ad hoc: Evotec and Celgene enter into strategic oncology partnership
Hamburg, Germany, 21 May 2018

Evotec AG announced today that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.

Ad hoc: Evotec AG plans conversion into European Company (SE)
Hamburg, Germany, 27 March 2018

Evotec AG today decided to begin preparations for legal conversion of the Company into a European Company (Societas Europaea, SE). The proposal, which has already been approved by the Supervisory Board, will be put to a vote at this year’s Annual General Meeting on 20 June 2018.

Ad hoc: Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform
Hamburg, Germany, 08 March 2018
Evotec AG today announced that Evotec and Sanofi have entered into exclusive negotiations to accelerate infectious disease research and development through a new open innovation platform led by Evotec.
2017
Ad hoc: Evotec AG to acquire Aptuit
Hamburg, Germany, 30 July 2017

Evotec AG today announced that it has entered into a definitive agreement with Aptuit Holdings LLC ("Aptuit") under which Evotec will acquire all operational business of Aptuit for $ 300 m (approx. EUR 256 m) to combine the businesses and expand Evotec's role as leading player in integrated outsourced drug discovery and development solutions.

Ad hoc: Novo A/S becomes new long-term strategic shareholder in Evotec
Hamburg, Germany, 09 February 2017

Evotec AG today announced that it resolved on a capital increase from its authorised capital against cash.

2016
Ad hoc: Evotec and Celgene enter into drug discovery collaboration for neurodegenerative diseases
Hamburg, Germany, 15 December 2016

Evotec AG announced today that Evotec and Celgene Corporation have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases. Initial disease areas of focus will include Amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple other neurodegenerative disorders.

Ad hoc: Evotec AG announces its intent to acquire Cyprotex PLC
Hamburg, Germany, 26 October 2016

Evotec AG today announced that it has made an offer to acquire Cyprotex PLC (AIM Listing: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in UK. The proposed acquisition, which has been unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016.

Ad hoc: Evotec AG increases its profitability guidance for 2016
Hamburg, Germany, 19 July 2016

Evotec AG today announced that, in the context of the half year results published on 10 August 2016, it increases its financial guidance for the current year.

2015
Evotec AG increases its revenue guidance for 2015
Hamburg, Germany, 15 September 2015

Evotec AG today announced that it increases its financial guidance for the current year.

Evotec's partner Roche provides initial update from Phase IIb trial in Alzheimer's disease
Hamburg, Germany, 30 June 2015
30 June 2015 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) was updated today by its partner Roche (SIX: RO, ROG; OTCQX: RHHBY) on the initial results of the Phase IIb ...
Evotec and Sanofi sign definitive agreement for major multi-component strategic alliance
Hamburg, Germany, 20 March 2015
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced the signing of a definitive agreement for a major multi-component strategic alliance over the next five ...
2014
Evotec and Sanofi enter into exclusive negotiations for a major multi-component strategic collaboration
, 02 December 2014
Hamburg, Germany - 02 December 2014: Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced today that it has entered into exclusive negotiations with Sanofi on a major multi-component ...
Evotec announces update on DiaPep277®
Hamburg, Germany, 08 September 2014

Evotec AG was informed that US company Hyperion Therapeutics, Inc. is terminating the development of DiaPep277(R) for newly diagnosed Type 1 diabetes.

2013
Evotec AG: Results of pre-clinical studies lead to reduction in revenues, nevertheless profitable and more than EUR 90 m cash for 2013 confirmed
Hamburg, Germany, 13 December 2013

Evotec AG today announced that it is adjusting its guidance regarding Group revenues.

Evotec raises EUR 30 m from Biotechnology Value Fund
Hamburg, Germany, 31 August 2013
Hamburg, Germany, 31 August 2013 - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced a capital increase against cash contribution by issuing 11,818,613 new shares to Biotechnology ...
Evotec to realign Discovery Chemistry Operations
Hamburg, Germany, 08 July 2013
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it will close its Chemistry Operations in Thane, India. All chemistry efforts will now be performed ...
2012
Evotec announces NMDA antagonist license agreement
Hamburg, Germany, 17 December 2012
Hamburg, Germany - 17 December 2012: Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it has entered into a license agreement with Janssen Pharmaceuticals, Inc. ...
Shifted Milestone Income Leads to Reduction in Operating Income Guidance for the Fiscal Year 2012
Hamburg, Germany, 19 October 2012

Evotec AG  today announced that it is adjusting its guidance regarding profitability on operating income for the fiscal year 2012.

Evotec and Bayer enter into multi-target alliance to fight endometriosis
Hamburg, Germany, 01 October 2012

Evotec AG that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.

CureBeta, a collaboration between Evotec AG and Harvard University enters strategic alliance with Janssen Pharmaceuticals
Hamburg, Germany, 10 July 2012

Evotec AG today announced that it has entered into a license and collaboration agreement with Janssen Pharmaceuticals, Inc. with a particular focus on the regeneration of insulin- producing beta cells.

2011
Ad hoc: Evotec and Roche agree to develop compound that could slow the progression of Alzheimer’s disease
Hamburg, Germany, 05 September 2011

Evotec AG and Roche AG today announced that they have entered into an exclusive world-wide license agreement for the development and commercialisation of Evotec’s MAO-B inhibitor to treat Alzheimer’s disease.

Ad hoc:Evotec acquires compound management business from Galapagos
Hamburg, Germany, 01 June 2011
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, TecDAX, ISIN: DE 000 566480 9) and Galapagos NV (Euronext: GLPG) today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, ...
Ad hoc: Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated
Hamburg, Germany, 18 May 2011
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, TecDAX, ISIN: DE 000 566480 9) and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type ...
Ad hoc:Evotec acquires Kinaxo, expanding its drug discovery platform with cutting-edge technologies
Hamburg, Germany, 09 February 2011
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based ...
2010
Ad hoc:Evotec announces metabolic disease alliance with MedImmune
Hamburg, Germany, 15 December 2010
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with ...
Ad hoc:Strong Milestone Income Leads to Profitable First Half for Evotec and Increase in Revenue Guidance for the Fiscal Year 2010
Hamburg, Germany, 12 August 2010
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today reported financial results and corporate updates for the first half of 2010. Group revenues grew significantly by ...
Ad hoc: Evotec Strengthens Discovery Alliance Business through Acquisition of DeveloGen
Hamburg, Germany, 14 July 2010
Hamburg, Germany - 14 July 2010 - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company ...
2009
Ad hoc: Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration
Hamburg, Germany, 09 November 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480, TecDAX) today announced that it has extended the research collaboration with Boehringer Ingelheim for a further 4 years. The collaboration ...
Ad hoc: Evotec starts Phase I with EVT 103, an NR2B-selective NMDA receptor antagonist
Hamburg, Germany, 08 September 2009
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today the Phase I clinical study initiation for EVT 103, a small molecule NR2B-selective NMDA receptor antagonist. EVT 103 is a next generation ...
Ad hoc: Evotec Accelerates Growth Strategy of its Discovery Alliance Business with Acquisition of Indian RSIPL
Hamburg, Germany, 06 August 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) and DIL Limited, India, announced today the signing of a definitive agreement to acquire a 70% controlling majority stake of the drug ...
Ad hoc: Evotec Announces the Successful Completion of the First Phase I Study with EVT 401
Hamburg, Germany, 29 June 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced the successful completion of the first Phase I study with its P2X7 receptor antagonist EVT 401. EVT 401 is a small molecule ...
Ad hoc: Evotec Acquires Zebrafish Screening Operations of Summit Corporation
Hamburg, Germany, 07 May 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that the Company will acquire the zebrafish screening operations of Summit Corporation plc, including operations in Abingdon, ...
Ad hoc: Evotec to Re-engineer Drug Discovery and Development Operations
Hamburg, Germany, 05 May 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that in the context of its Evotec 2012 - Action Plan to Focus and Grow, the Company is re-engineering its drug discovery and ...
Ad hoc: Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302
Hamburg, Germany, 14 April 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced the results of a Phase II proof-of-concept study investigating the potential of EVT 302, a reversible and highly selective ...
Ad hoc: Evotec Restructures and Implements \"Evotec 2012 - Action Plan to Focus and Grow\"
, 27 March 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today decided that it will restructure to focus on core value programs and significantly reduce its operating costs. This follows the ...
Ad hoc: Evotec and Roche to Develop EVT 101 for Treatment-Resistant Depression
, 09 March 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) and Roche announced today that they have entered into an agreement for Phase II clinical development of EVT 101 in patients with ...
Ad hoc: Evotec Appoints Dr. Werner Lanthaler as Chief Executive Officer
Hamburg, Germany, 06 March 2009
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced today the appointment of Dr. Werner Lanthaler as Chief Executive Officer of the Company, effective immediately. In his previous ...
2008
Ad hoc: Jörn Aldag resigns as CEO of Evotec AG
Hamburg, Germany, 10 December 2008
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced today that Jörn Aldag will resign from his position as President & Chief Executive Officer of Evotec. The resignation will ...
Ad hoc: Renovis Stockholders Approve Acquisition by Evotec
Hamburg, Germany, 01 May 2008
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that the stockholders of Renovis, Inc. (NASDAQ: RNVS) approved the adoption of the merger agreement with Evotec at a special ...
2007
Ad hoc: Evotec Reports Positive Top-Line Results in Phase II Study with EVT 201 in Elderly Insomniacs with Daytime Sleepiness
Hamburg, Germany, 16 October 2007
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today completed the top-line analysis of its double-blind, placebo-controlled, parallel group design phase II trial of EVT 201 1.5 mg and 2.5 ...
Ad hoc: Evotec to Acquire Renovis, Seek NASDAQ Listing
Hamburg, Germany, 19 September 2007
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) and Renovis, Inc., South San Francisco, California, US, today announced that they have entered into a definitive agreement under which Evotec ...
Ad hoc: Evotec Sells its Chemical Development Business to Aptuit for GBP 31.5m (approx. EUR 46.4m) in Cash
Hamburg, Germany, 10 September 2007
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it has sold its Chemical Development Business to Aptuit, Inc., Greenwich, CT, US, for approximately EUR 46.4 m in cash. ...
Ad hoc: Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
Hamburg, Germany, 04 June 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced today positive top-line results from its first phase II clinical trial of EVT 201 in patients with ...
Ad hoc: Evotec to Acquire Neuro3d
Hamburg, Germany, 29 March 2007
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced the acquisition of all shares of Neuro3d S.A., Mulhouse, France, with all assets contained ...
2006
Hugin Ad hoc announcement according to § 15 WpHG: Acquisition: Evotec AG: PerkinElmer to Acquire Evotec Technologies
Hamburg, Germany, 01 December 2006
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that the Company has signed a definitive agreement with PerkinElmer pursuant to which PerkinElmer will acquire Evotec ...
Hugin Ad hoc announcement according to § 15 WpHG: Misc. matters: Evotec AG: Evotec Initiates Phase II Clinical Trial with EVT 201 for the Treatment of Insomnia
Hamburg, Germany, 21 September 2006
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today initiated a Phase II clinical trial with EVT 201 for the treatment of insomnia under a US IND. This US, ...
Hugin Ad hoc announcement according to § 15 WpHG: Misc. strategic decisions: Evotec AG: Evotec Discontinues EVT 301 Development Programme
Hamburg, Germany, 13 September 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today reported that during the one month safety and tolerability study with EVT 301 in young and elderly ...
Ad hoc: Evotec Reports Preliminary Q2 Summary Results
Hamburg, Germany, 24 July 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today reported preliminary results of the second quarter 2006. Group revenues grew 2% over Q2 2005, to EUR ...
Ad hoc: Offering of Evotec Shares Successfully Completed
Hamburg, Germany, 27 April 2006
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced that today 5,228,701 Evotec shares were successfully placed by DZ BANK AG, Frankfurt, as Sole Lead ...
Ad hoc: Evotec Intends to Raise Approximately EUR 18 Million in a Share Capital Increase
Hamburg, Germany, and Oxford, UK, 26 April 2006
  Hamburg, Germany, and Oxford, UK, 26.04.2006 Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that the Management Board and Supervisory Board have decided to increase ...
Ad hoc: Evotec Exceeds Revenue Target for 2005
Hamburg, Germany, 04 January 2006
Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it exceeded its revenue target for the financial year 2005 of "up to 5%" growth over 2004 (2004: EUR 72.7 million). ...
2005
Ad hoc: Evotec OAI Announces In-licensing of a Compound
Hamburg, Germany, 18 March 2005
Hamburg, Germany | Oxford, UK - Evotec OAI AG announces today that its soon to be 100%-owned subsidiary Evotec Neurosciences GmbH (ENS) has in-licensed a compound from an unnamed third party which has safely completed a ...
Ad hoc: Evotec Acquires ENS and Secures € 47m in Cash to Develop CNS Pipeline
Hamburg, Germany, 06 March 2005
Evotec OAI AG (Evotec) today announces the acquisition of the outstanding 78% of Evotec Neurosciences (ENS Holdings, Inc., ENS) not already owned by Evotec. ENS discovers and develops therapeutics for the treatment of Alzheimer's ...
2004
Ad hoc: Evotec OAI Updates Guidance for 2004 and Provides Preliminary Third Quarter Revenues
Hamburg, Germany, 20 October 2004
For the first nine months of 2004 Evotec OAI's (WKN 566480) revenues reached EUR 47.4m (2003: EUR 56.7m). In the third quarter, revenues amounted to EUR 16.1m, down 26% over Q3 of the previous year (2003: EUR 21.9m). The decline ...
Ad Hoc: Evotec OAI Intends to Increase its Share Capital
Hamburg, Germany, 14 July 2004
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that the Management Board decided to increase its share capital against contribution in cash from authorised capital, ...
Ad hoc: Offering of Evotec OAI Shares Successfully Completed
Hamburg, Germany, 14 July 2004
Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announced that today 2,500,000 Evotec OAI shares were successfully placed by Sal. Oppenheim as Global Co-ordinator and bookrunner. The new ...

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard
TOP